<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Bisphosphonates for steroid‐induced osteoporosis - Allen, CS - 2016 | Cochrane Library</title> <meta content="Bisphosphonates for steroid‐induced osteoporosis - Allen, CS - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001347.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Bisphosphonates for steroid‐induced osteoporosis - Allen, CS - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001347.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001347.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Bisphosphonates for steroid‐induced osteoporosis" name="citation_title"/> <meta content="Claire S Allen" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="James HS Yeung" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Ben Vandermeer" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Joanne Homik" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="joanne.homik@ualberta.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD001347.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001347.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001347.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001347.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bone Density Conservation Agents [*therapeutic use]; Diphosphonates [*therapeutic use]; Glucocorticoids [*adverse effects]; Osteoporosis [*chemically induced, *prevention &amp; control]; Randomized Controlled Trials as Topic; Spinal Fractures [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001347.pub2&amp;doi=10.1002/14651858.CD001347.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001347\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001347\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","pt","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001347.pub2",title:"Bisphosphonates for steroid\\u2010induced osteoporosis",firstPublishedDate:"Oct 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001347.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001347.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001347.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001347.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001347.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001347.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001347.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001347.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001347.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001347.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7422 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001347.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0120"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/appendices#CD001347-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/table_n/CD001347StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/table_n/CD001347StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Bisphosphonates for steroid‐induced osteoporosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#CD001347-cr-0002">Claire S Allen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#CD001347-cr-0003">James HS Yeung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#CD001347-cr-0004">Ben Vandermeer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information#CD001347-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Joanne Homik</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information/en#CD001347-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001347.pub2">https://doi.org/10.1002/14651858.CD001347.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001347-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001347-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001347-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001347-abs-0001" lang="en"> <section id="CD001347-sec-0001"> <h3 class="title" id="CD001347-sec-0001">Background</h3> <p>This is an update of a Cochrane Review first published in 1999. Corticosteroids are widely used in inflammatory conditions as an immunosuppressive agent. Bone loss is a serious side effect of this therapy. Several studies have examined the use of bisphosphonates in the prevention and treatment of glucocorticosteroid‐induced osteoporosis (GIOP) and have reported varying magnitudes of effect. </p> </section> <section id="CD001347-sec-0002"> <h3 class="title" id="CD001347-sec-0002">Objectives</h3> <p>To assess the benefits and harms of bisphosphonates for the prevention and treatment of GIOP in adults. </p> </section> <section id="CD001347-sec-0003"> <h3 class="title" id="CD001347-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE and Embase up to April 2016 and International Pharmaceutical Abstracts (IPA) via OVID up to January 2012 for relevant articles and conference proceedings with no language restrictions. We searched two clinical trial registries for ongoing and recently completed studies (ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal). We also reviewed reference lists of relevant review articles. </p> </section> <section id="CD001347-sec-0004"> <h3 class="title" id="CD001347-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) satisfying the following criteria: 1) prevention or treatment of GIOP; 2) adults taking a mean steroid dose of 5.0 mg/day or more; 3) active treatment including bisphosphonates of any type alone or in combination with calcium or vitamin D; 4) comparator treatment including a control of calcium or vitamin D, or both, alone or with placebo; and 4) reporting relevant outcomes. We excluded trials that included people with transplant‐associated steroid use. </p> </section> <section id="CD001347-sec-0005"> <h3 class="title" id="CD001347-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently selected trials for inclusion, extracted data, performed ‘risk of bias’ assessment and evaluated the certainty of evidence using the GRADE approach. Major outcomes of interest were the incidence of vertebral and nonvertebral fractures after 12 to 24 months; the change in bone mineral density (BMD) at the lumbar spine and femoral neck after 12 months; serious adverse events; withdrawals due to adverse events; and quality of life. We used standard Cochrane methodological procedures. </p> </section> <section id="CD001347-sec-0006"> <h3 class="title" id="CD001347-sec-0006">Main results</h3> <p>We included a total of 27 RCTs with 3075 participants in the review. Pooled analysis for incident vertebral fractures included 12 trials (1343 participants) with high‐certainty evidence and low risk of bias. In this analysis 46/597 (or 77 per 1000) people experienced new vertebral fractures in the control group compared with 31/746 (or 44 per 1000; range 27 to 70) in the bisphosphonate group; relative improvement of 43% (9% to 65% better) with bisphosphonates; absolute increased benefit of 2% fewer people sustaining fractures with bisphosphonates (5% fewer to 1% more); number needed to treat for an additional beneficial outcome (NNTB) was 31 (20 to 145) meaning that approximately 31 people would need to be treated with bisphosphonates to prevent new vertebral fractures in one person. </p> <p>Pooled analysis for incident nonvertebral fractures included nine trials with 1245 participants with low‐certainty evidence (downgraded for imprecision and serious risk of bias as a patient‐reported outcome). In this analysis 30/546 (or 55 per 1000) people experienced new nonvertebral fracture in the control group compared with 29/699 (or 42 per 1000; range 25 to 69) in the bisphosphonate group; relative improvement of 21% with bisphosphonates (33% worse to 53% better); absolute increased benefit of 1% fewer people with fractures with bisphosphonates (4% fewer to 1% more). </p> <p>Pooled analysis on BMD change at the lumbar spine after 12 months included 23 trials with 2042 patients. Eighteen trials with 1665 participants were included in the pooled analysis on BMD at the femoral neck after 12 months. Evidence for both outcomes was moderate‐certainty (downgraded for indirectness as a surrogate marker for osteoporosis) with low risk of bias. Overall, the bisphosphonate groups reported stabilisation or increase in BMD, while the control groups showed decreased BMD over the study period. At the lumbar spine, there was an absolute increase in BMD of 3.5% with bisphosphonates (2.90% to 4.10% higher) with a relative improvement of 1.10% with bisphosphonates (0.91% to 1.29%); NNTB 3 (2 to 3). At the femoral neck, the absolute difference in BMD was 2.06% higher in the bisphosphonate group compared to the control group (1.45% to 2.68% higher) with a relative improvement of 1.29% (0.91% to 1.69%); NNTB 5 (4 to 7). </p> <p>Pooled analysis on serious adverse events included 15 trials (1703 participants) with low‐certainty evidence (downgraded for imprecision and risk of bias). In this analysis 131/811 (or 162 per 1000) people experienced serious adverse events in the control group compared to 136/892 (or 147 per 1000; range 120 to 181) in the bisphosphonate group; absolute increased harm of 0% more serious adverse events (2% fewer to 2% more); a relative per cent change with 9% improvement (12% worse to 26% better). </p> <p>Pooled analysis for withdrawals due to adverse events included 15 trials (1790 patients) with low‐certainty evidence (downgraded for imprecision and risk of bias). In this analysis 63/866 (or 73 per 1000) people withdrew in the control group compared to 76/924 (or 77 per 1000; range 56 to 107) in the bisphosphonate group; an absolute increased harm of 1% more withdrawals with bisphosphonates (95% CI 1% fewer to 3% more); a relative per cent change 6% worse (95% CI 47% worse to 23% better). </p> <p>Quality of life was not assessed in any of the trials.</p> </section> <section id="CD001347-sec-0007"> <h3 class="title" id="CD001347-sec-0007">Authors' conclusions</h3> <p>There was high‐certainty evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures with data extending to 24 months of use. There was low‐certainty evidence that bisphosphonates may make little or no difference in preventing nonvertebral fractures. There was moderate‐certainty evidence that bisphosphonates are beneficial in preventing and treating corticosteroid‐induced bone loss at both the lumbar spine and femoral neck. Regarding harm, there was low‐certainty evidence that bisphosphonates may make little or no difference in the occurrence of serious adverse events or withdrawals due to adverse events. We are cautious in interpreting these data as markers for harm and tolerability due to the potential for bias. </p> <p>Overall, our review supports the use of bisphosphonates to reduce the risk of vertebral fractures and the prevention and treatment of steroid‐induced bone loss. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001347-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001347-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001347-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001347-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001347-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001347-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001347-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001347-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001347-abs-0004" lang="en"> <h3>Bisphosphonates for treating osteoporosis caused by the use of steroids</h3> <p><b>Background</b> </p> <p>Steroids (glucocorticosteroids) are widely used to treat inflammation. Bone loss (osteoporosis) and spinal fractures are serious side effects of this therapy. Bisphosphonates are considered a first‐line treatment for osteoporosis and have been used since the 1990s. </p> <p><b>Methods</b> </p> <p>We examined the research published up to April 2016 and found a total of 27 eligible trials, which included 3075 adults with inflammatory diseases that required steroid treatment for at least one year. People were randomly assigned to receive either bisphosphonate treatment (alone or with calcium or vitamin D, or both) or 'no treatment' (given calcium or vitamin D or a placebo). Our objective was to determine the benefits and harms of bisphosphonates for adults on long‐term steroid therapy. </p> <p><b>Main Results</b> </p> <p><i>New spinal fractures (12 to 24 months)</i> </p> <p>There were 12 trials with 1343 people for this analysis. We found that 77 per 1000 people with no treatment experienced new spinal fracture compared to 44 per 1000 (range 27 to 70) people taking bisphosphonates; an absolute benefit of 2% fewer people (5% fewer to 1% more) sustaining spinal fractures when taking bisphosphonates. </p> <p>Approximately 31 people (range 20 to 145) would need to be treated with bisphosphonates to prevent spinal fractures in one person. </p> <p><i>New non‐spinal fractures (12 to 24 months)</i> </p> <p>There were nine trials with 1245 people for this analysis. We found that 55 per 1000 people with no treatment experienced new non‐spinal fractures compared to 42 per 1000 (range 25 to 69) people taking bisphosphonates; an absolute benefit of 1% fewer people (4% fewer to 1% more) sustaining non‐spinal fractures when taking bisphosphonates. </p> <p><i>Lumbar spine bone mineral density (BMD) at 12 months</i> </p> <p>There were 23 trials with 2042 people for this outcome. We found that the BMD of the lumbar spine of people taking bisphosphonates was 3.50% higher (2.90% to 4.10% higher) than in people who had no treatment. </p> <p>Approximately three people (range 2 to 3) would need to be treated with bisphosphonates for 12 months for one person to see a minimally important difference in BMD at the lumbar spine. </p> <p><i>Femoral neck (top of thigh bone) BMD at 12 months</i> </p> <p>There were 18 trials with 1665 people for this outcome. We found that the BMD of the femoral neck was 2.06% higher in the bisphosphonate group (1.45% to 2.68% more) than in people with no treatment. </p> <p>Approximately five people (range 4 to 7) would need to be treated with bisphosphonates for 12 months for one person to see a minimally important difference in BMD at the femoral neck. </p> <p><i>Serious adverse events (requiring hospitalisations, life threatening or fatal)</i> </p> <p>There were 15 trials with 1703 people for this outcome. We found that 162 per 1000 people with no treatment experienced serious adverse events compared to 147 per 1000 (range 120 to 181) taking bisphosphonates; an absolute increased harm of 0% more serious adverse events (2% fewer to 2% more) with bisphosphonates. </p> <p><i>Withdrawals due to adverse events</i> </p> <p>There were 15 trials with 1790 people for this outcome. We found that 73 per 1000 people with no treatment withdrew compared to 77 per 1000 (range 56 to 107) people taking bisphosphonates; an absolute increased harm of 1% more withdrawals due to adverse events (1% fewer to 3% more) with bisphosphonates. </p> <p><b>Authors' conclusions</b> </p> <p>Based on moderate‐ to high‐certainty evidence, we found that bisphosphonates are beneficial in preventing new spinal fractures and preventing and treating steroid‐induced bone loss at the lumbar spine and femoral neck. For preventing non‐spinal fractures, we found that there was little or no difference whether patients used bisphosphonates or not, although this evidence was low‐certainty because the methods used to assess non‐spinal fractures were subject to bias. </p> <p>We found that there was little or no difference in the number of serious adverse events or withdrawals due to adverse events when comparing bisphosphonates to no treatment. The evidence for these outcomes was of low certainty and we are cautious in making firm conclusions about the harm of bisphosphonates based only on these measures. </p> <p>Overall, our review supports the use of bisphosphonates to reduce the risk of spinal fractures and in the prevention and treatment of steroid‐induced bone loss. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001347-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-sec-0120">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-sec-0173">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001347-sec-0120"></div> <h3 class="title" id="CD001347-sec-0121">Implications for practice</h3> <section id="CD001347-sec-0121"> <p>There is high‐certainty evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures in people on corticosteroids with data extending to 24 months of use. There is moderate‐certainty evidence that bisphosphonates are beneficial in preventing and treating corticosteroid‐induced bone loss at both the lumbar spine and femoral neck. Though the magnitude of effect on BMD differs between sites and whether used for treatment or prophylaxis, in all groups there are statistically and clinically relevant findings. There was low‐certainty evidence that bisphosphonates may make little or no difference in preventing nonvertebral fractures, although the low number of events reported in all studies makes it difficult to show a benefit without a larger sample size. </p> <p>Prophylactic therapy demonstrates an ability to reduce bone loss, whereas treatment of GIOP provides an opportunity to build bone mass in chronic steroid‐using patients. There is a trend toward greater benefit with the use of IV bisphosphonates although this review was not set up as a comparative effectiveness analysis. Notions of increased efficacy in IV therapy as compared to oral have yet to be firmly established in the setting of GIOP. It was interesting to see that low‐dose bisphosphonate regimes had only a slightly lower benefit as compared to standard doses given the poor absorption of oral bisphosphonates. </p> <p>Bisphosphonates are generally well tolerated with the number of reported side effects being similar between treatment and placebo groups. Upper gastrointestinal symptoms and musculoskeletal pain are the most common side effects reported and are typically mild in nature. There was low‐certainty evidence that bisphosphonates may make little or no difference in serious adverse events or withdrawals due to adverse events. </p> <p>We conclude that the outcomes assessed in this review are important in terms of their impact on decisions regarding optimal GIOP management. Based on the currently available moderate‐ to high‐certainty evidence, our review supports the use of bisphosphonates to reduce the risk of vertebral fractures and the prevention and treatment of steroid‐induced bone loss and is consistent with current guidelines. </p> </section> <h3 class="title" id="CD001347-sec-0122">Implications for research</h3> <section id="CD001347-sec-0122"> <p>Further high‐quality research on vertebral fractures is unlikely to substantially change the conclusions of this review. The benefits of bisphosphonates in the prevention and treatment of GIOP is well established when BMD data are used as surrogate markers for fracture risk. More research needs to be conducted into long‐term nonvertebral fracture prevention in this patient population. Recommendations regarding the routine use of these medications in people on corticosteroids require further research to answer questions regarding cost‐effectiveness. Further head‐to‐head trials comparing parenteral to oral bisphosphonates with fracture outcome data are needed to investigate the potential increased efficacy of parenteral bisphosphonates in GIOP. Finally, confirmation regarding the efficacy of low‐dose bisphosphonates in the GIOP population is required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001347-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001347-sec-0022"></div> <div class="table" id="CD001347-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates versus control for adults with GIOP</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonates (alone or with calcium and/or vitamin D) compared with control (calcium and/or vitamin D and/or placebo) for adults with GIOP</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with GIOP </p> <p><b>Settings:</b> ambulatory </p> <p><b>Intervention:</b> bisphosphonates (alone or with calcium and/or vitamin D) </p> <p><b>Comparison:</b> control (calcium and/or vitamin D and/or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (calcium and/or vitamin D and/or placebo)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bisphosphonates (alone or with calcium and/or vitamin D) </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident vertebral fractures</b> </p> <p>Radiographic follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (27 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.35 to 0.91) </p> <p><b>RD ‐0.02</b> (‐0.05 to </p> <p>0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1343<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute increased benefit 2% fewer people with fractures using bisphosphonates (95% CI 5.00% fewer to 1.00% more) </p> <p>Relative per cent change 43% improvement with bisphosphonates (95% CI 9.00% to 65.00% better) </p> <p>NNTB = 31 (95% CI 20 to 145)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incident nonvertebral fractures</b> </p> <p>Radiographic follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> <br/> (25 to 69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.79</b> (0.47 to 1.33) </p> <p><b>RD ‐0.01</b> (‐0.04 to 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1245<br/> (9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased benefit 1% fewer people with fractures using bisphosphonates (95% CI 4.00% fewer to 1.00% more) </p> <p>Relative per cent change 21% improvement with bisphosphonates (95% CI 33.00% worse to 53.00% better) </p> <p>NNTB = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lumbar spine BMD</b> </p> <p>DEXA follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean per cent change in BMD across control groups was <b>‐3.19%</b> (‐8.08% to 1.70%) from baseline<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean per cent change in BMD from baseline in bisphosphonate groups was <b>3.50% higher</b> than control groups (2.90% to 4.10% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2042<br/> (23 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,7,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute increased benefit 3.50% with bisphosphonates (95% CI 2.90 to 4.10)</p> <p>Relative per cent change 1.10% (95% CI 0.91 to 1.29) with bisphosphonates</p> <p>NNTB = 3 (95% CI 2 to 3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Femoral neck BMD</b> </p> <p>DEXA follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean per cent change in BMD across control groups was <b>‐1.59%</b> (‐10.49% to 7.31%) from baseline <sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean per cent change in BMD from baseline in bisphosphonate groups was <b>2.06% higher</b> than control groups (1.45% to 2.68% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1665<br/> (18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased benefit 2.06% with bisphosphonates (95% CI 1.45 to 2.68)</p> <p>Relative per cent change 1.29% with bisphosphonates (95% CI 0.91 to 1.69)</p> <p>NNTB = 5 (95% CI 4 to 7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p>follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>147 per 1000</b> <br/> (120 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b> (0.74 to 1.12) </p> <p><b>RD 0.00</b> (‐0.02, 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1703<br/> (15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>low</b><sup>3,9</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased harm 0% more adverse events with bisphosphonates (95% CI 2.00% fewer to 2.00% more) </p> <p>Relative per cent change 9% improvement with bisphosphonates (95% CI 12.00% worse to 26.00% better) </p> <p>NNTH = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> <p>follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>77 per 1000</b> <br/> (56 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.06</b> (0.77 to 1.47) </p> <p><b>RD 0.01</b> (‐0.01 to 0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1790<br/> (15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>low</b><sup>3,9</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased harm 1% more withdrawals with bisphosphonates (95% CI 1.00% fewer to 3.00% more) </p> <p>Relative per cent change 6% worsening with bisphosphonates (95% CI 47.00% worse to 23.00% better) </p> <p>NNTH = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not assessed by any of the trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>RD:</b> Risk Difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Vertebral fractures meet calculated OIS threshold of 1174 (calculation not shown ‐ <a href="./references#CD001347-bbs2-0056" title="Brant , R . Inference for Proportions: Comparing Two Independent Samples. Accessed June 12 2015: stat.ubc.ca/˜rollin/stats/ssize/b2.html, 2014. ">Brant 2014</a>) </p> <p><sup>2</sup>Downgraded for risk of bias: nonvertebral fractures were a patient‐reported, subjective outcome </p> <p><sup>3</sup>Downgraded for imprecision: total sample size is below calculated optimal information size (OIS) (calculations not shown ‐ <a href="./references#CD001347-bbs2-0056" title="Brant , R . Inference for Proportions: Comparing Two Independent Samples. Accessed June 12 2015: stat.ubc.ca/˜rollin/stats/ssize/b2.html, 2014. ">Brant 2014</a>) and the 95% confidence interval around the pooled estimate of effect includes both the possibility of no effect and appreciable benefit or harm </p> <p><sup>4</sup>Number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) is not applicable when result is not statistically significant </p> <p><sup>5</sup>We calculated mean baseline risk for the control group in RevMan using generic inverse variance (calculations not shown) </p> <p><sup>6</sup>Most heterogeneity explained through sensitivity analyses </p> <p><sup>7</sup>Downgraded for indirectness: bone density is a surrogate marker for fracture risk </p> <p><sup>8</sup>Clinically relevant change in BMD: the natural history of participants starting steroid therapy based on control arms in our prevention trials is to see a 1%‐6% decrease in lumbar spine BMD and 1%‐4% decrease in femoral neck BMD in the first year of treatment. We have used an SMD of 0.5 as an estimate of the minimal clinically important difference for BMD change to calculate the NNTB (<a href="./references#CD001347-bbs2-0092" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.handbook.cochrane.org. ">Schünemann 2011b</a>) </p> <p><sup>9</sup>Downgraded for risk of bias: the protocols for the collection of harm data in a large number of trials were unclear </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001347-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-sec-0146">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD001347-sec-0023"></div> <section id="CD001347-sec-0024"> <h3 class="title" id="CD001347-sec-0024">Description of the condition</h3> <p>Corticosteroids are widely used in inflammatory conditions as an immunosuppressive agent. Diseases treated with corticosteroids include connective tissue diseases, respiratory diseases, haematological diseases, inflammatory bowel disease and organ transplantation. Bone loss is a serious side effect of this therapy, commonly referred to as glucocorticoid‐induced osteoporosis (GIOP), and is likely mediated through a variety of mechanisms. </p> <p>The most widely accepted mechanisms in the pathogenesis of GIOP are the direct inhibition of bone formation and increase in bone resorption. Inhibition of bone formation is mediated by a decrease in osteoblast differentiation, impaired maturation and function, and premature osteoblast apoptotic death, as evidenced by decreased serum osteocalcin levels (<a href="./references#CD001347-bbs2-0057" title="CanalisE , MazziottiG , GiustinaA , BilezikianJP . Glucocorticoid‐induced osteoporosis: pathophysiology and therapy. Osteoporosis International2007;18:1319‐28. ">Canalis 2007</a>; <a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>). Glucocorticoids enhance osteoclast‐mediated bone resorption by suppressing osteoprotegerin; stimulating RANK/RANKL; and decreasing apoptosis, all of which result in increased levels of osteoclasts. There is also evidence of decreased calcium absorption, increased calcium excretion and decreased serum concentration of sex hormones (<a href="./references#CD001347-bbs2-0057" title="CanalisE , MazziottiG , GiustinaA , BilezikianJP . Glucocorticoid‐induced osteoporosis: pathophysiology and therapy. Osteoporosis International2007;18:1319‐28. ">Canalis 2007</a>; <a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>). In addition to their effect on bone density, steroids are known to affect bone architecture and quality (<a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a>; <a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>; <a href="./references#CD001347-bbs2-0096" title="VanStaaTP , LeufkensHGM , CooperC . The Epidemiology of Corticosteroid‐Induced Osteoporosis: a Meta‐analysis. Osteoporosis International2002;13:777‐87. ">Van Staa 2002</a>). These two factors likely contribute to a lower BMD threshold for fracture in people with GIOP. </p> <p>There is controversy in the literature regarding the minimum dose and duration of corticosteroids required to produce bone loss and fractures, with reports of doses as low as 2.5 to 7.5 mg/day leading to statistically significant bone loss and a 2.5 fold increase in vertebral fractures (<a href="./references#CD001347-bbs2-0057" title="CanalisE , MazziottiG , GiustinaA , BilezikianJP . Glucocorticoid‐induced osteoporosis: pathophysiology and therapy. Osteoporosis International2007;18:1319‐28. ">Canalis 2007</a>; <a href="./references#CD001347-bbs2-0094" title="SteinbuchM , ThomasE , YouketTE , CohenS . Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporosis International2004;15:323‐8. ">Steinbuch 2004</a>; <a href="./references#CD001347-bbs2-0096" title="VanStaaTP , LeufkensHGM , CooperC . The Epidemiology of Corticosteroid‐Induced Osteoporosis: a Meta‐analysis. Osteoporosis International2002;13:777‐87. ">Van Staa 2002</a>). Fracture risk may be confounded by the underlying inflammatory disease processes themselves, which may independently lead to bone loss and fractures (<a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>). </p> </section> <section id="CD001347-sec-0025"> <h3 class="title" id="CD001347-sec-0025">Description of the intervention</h3> <p>Bisphosphonates have been used to treat osteoporosis since the 1990s and are considered to be first line treatment when pharmacological therapy is recommended. Various types of bisphosphonates exist, most commonly in oral pill form, although intravenous bisphosphonates are also available and in North America are reserved traditionally for individuals who are unable to tolerate oral bisphosphonates. Oral regimes include daily or weekly administration, whereas intravenous bisphosphonates are administered every few months or on a yearly basis (<a href="./references#CD001347-bbs2-0083" title="National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014. ">National Osteoporosis Foundation 2014</a>)<i>.</i> </p> </section> <section id="CD001347-sec-0026"> <h3 class="title" id="CD001347-sec-0026">How the intervention might work</h3> <p>Bisphosphonates reduce bone loss through various mechanisms of actions that are not fully understood. In general, bisphosphonates are shown to reduce the rate of bone turnover through a strong affinity for bone mineral, which translates to a decrease in bone loss. They also have an inhibitory effect that decreases the number and activity of osteoclasts, which dissolve bone as part of the normal bone turnover process (<a href="./references#CD001347-bbs2-0088" title="RussellRG , XiaZ , DunfordJE , OppermannU , KwaasiA , HulleyPA , et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Annals of the New York Academy of Sciences2007;1117:209‐57. ">Russell 2007</a>). Bisphosphonate efficacy, measured as per cent change in BMD over one year, ranges from ‐3% to +12% in bisphosphonate studies. </p> </section> <section id="CD001347-sec-0027"> <h3 class="title" id="CD001347-sec-0027">Why it is important to do this review</h3> <p>A consequence of low bone mass is the development of vertebral and nonvertebral fractures. GIOP often manifests as clinically silent until the development of a fracture. BMD is commonly used as an intermediate outcome to extrapolate fracture risk, however it should be noted that the correlation between BMD and fracture risk that exists in post‐menopausal osteoporosis has not been established in corticosteroid‐induced osteoporosis. Therefore it is important to have direct evidence of the benefit of bisphosphonates in reducing fracture risk in GIOP. </p> <p>The routine use of prophylactic therapy to prevent bone loss and fractures is suboptimal despite recommendations from American College of Rheumatology (ACR) practice guidelines (<a href="./references#CD001347-bbs2-0070" title="GrossmanJM , GordonR , RanganathVK , DealC , CaplanL , ChenW . American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Care and Research2010;62(11):1515‐26. ">Grossman 2010</a>). Recent North American prescription patterns for GIOP prevention demonstrate a prevalence of anti‐resorptive co‐prescription of only 15% to 37% in people receiving long‐term steroid treatment (<a href="./references#CD001347-bbs2-0061" title="CurtisJR , WestfallAO , AllisonJJ , BeckerA , CasebeerL , FreemanA , et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patients. Arthritis &amp; Rheumatism2005;52(8):2485‐94. ">Curtis 2005</a>; <a href="./references#CD001347-bbs2-0065" title="FeldsteinAC , ElmerPJ , NicholsGA , HersonM . Practice patterns in patients at risk for glucocorticoid‐induced osteoporosis. Osteoporosis International2005;16(12):2168‐74. ">Feldstein 2005</a>; <a href="./references#CD001347-bbs2-0080" title="McKeownE , VivianP , BykerkVP , DeLeonF , BonnerA , ThorneC , et al. Quality assurance study of the use of preventative therapies in glucocorticoid‐induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology2012;51:1662‐9. ">Mckeown 2012</a>). </p> <p>A Cochrane Systematic Review and meta‐analysis is useful to determine the benefits and harms of bisphosphonates in the prevention and treatment of GIOP and fractures in order to justify and encourage their routine use. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001347-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-sec-0151">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001347-sec-0028"></div> <p>To assess the benefits and harms of bisphosphonates for the prevention and treatment of GIOP in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001347-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-sec-0152">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001347-sec-0029"></div> <section id="CD001347-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001347-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCT).</p> </section> <section id="CD001347-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants were men or women over the age of 18 with underlying inflammatory disorders, initiating treatment or currently being treated with systemic corticosteroids, and who had not received bisphosphonates in the six months prior to the start of the study. We defined prevention studies by bisphosphonate treatment starting within three months of initiating corticosteroids, while treatment (secondary prevention) studies included those that initiated bisphosphonate treatment beyond three months of starting corticosteroid therapy. These definitions are widely used in GIOP literature and are based on the notion that rapid bone loss is seen within the first three to six months of corticosteroid use (<a href="./references#CD001347-bbs2-0057" title="CanalisE , MazziottiG , GiustinaA , BilezikianJP . Glucocorticoid‐induced osteoporosis: pathophysiology and therapy. Osteoporosis International2007;18:1319‐28. ">Canalis 2007</a>; <a href="./references#CD001347-bbs2-0096" title="VanStaaTP , LeufkensHGM , CooperC . The Epidemiology of Corticosteroid‐Induced Osteoporosis: a Meta‐analysis. Osteoporosis International2002;13:777‐87. ">Van Staa 2002</a>). </p> <p>Due to controversy in the literature regarding low‐dose steroids and the risk of osteoporosis and fracture, we used only those trials where the mean corticosteroid dose was 5 mg/day or higher. Participants had to be continuing corticosteroid treatment throughout the entire course of the study. We excluded trials that included people with transplant‐associated steroid use from the review. </p> </section> <section id="CD001347-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included trials that evaluated any bisphosphonate alone or in combination with calcium or vitamin D, or both, as the active treatment group. The control groups were taking calcium or vitamin D, or both, alone or with placebo. </p> </section> <section id="CD001347-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD001347-sec-0035"> <h5 class="title">Benefits</h5> <section id="CD001347-sec-0036"> <h6 class="title">Major outcomes</h6> <p> <ul id="CD001347-list-0001"> <li> <p>Number of participants with incident radiographic vertebral fractures.</p> </li> <li> <p>Number of participants with incident radiographic nonvertebral fractures.</p> </li> <li> <p>Per cent change in BMD of the lumbar spine and femoral neck measured by dual energy X‐ray absorptiometry (DEXA). </p> </li> <li> <p>Quality of life using any measurement tool.</p> </li> </ul> </p> </section> <section id="CD001347-sec-0037"> <h6 class="title">Minor outcomes</h6> <p> <ul id="CD001347-list-0002"> <li> <p>Per cent change in BMD of the lumbar spine using low‐dose versus standard‐dose bisphosphonates.</p> </li> <li> <p>Per cent change in BMD of the femoral neck using low‐dose versus standard‐dose bisphosphonates.</p> </li> </ul> </p> </section> </section> <section id="CD001347-sec-0038"> <h5 class="title">Harms</h5> <section id="CD001347-sec-0039"> <h6 class="title">Major outcomes</h6> <p> <ul id="CD001347-list-0003"> <li> <p>Serious adverse events (requiring hospitalisation, life threatening or fatal).</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ul> </p> </section> </section> <section id="CD001347-sec-0040"> <h5 class="title">Timing of outcome assessment</h5> <p> <ul id="CD001347-list-0004"> <li> <p>We extracted incident fracture data, serious adverse events and withdrawals due to adverse events for any time points where available. </p> </li> <li> <p>We extracted data for our BMD outcomes at 12 months and at 18 to 24 months for use in separate analyses. </p> </li> <li> <p>We extracted data on low‐dose versus standard‐dose bisphosphonates at 12 months.</p> </li> <li> <p>If data existed at multiple time points within the above periods, we only extracted data at the latest possible time point of each period. </p> </li> </ul> </p> </section> </section> </section> <section id="CD001347-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001347-sec-0042"> <h4 class="title">Electronic searches</h4> <p>The original review searched MEDLINE and Embase from inception to 1997 (<a href="https://archie.cochrane.org/sections/documents/view?version=z1607131841139166835206116318693%26format=REVMAN#APP-01" target="_blank">Appendix 1</a>). For this review update we searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 5, 2015); MEDLINE, Embase, and the International Pharmaceutical Abstracts (IPA) via OVID for relevant articles and conference proceedings. We also searched two clinical trials registries (ClinicalTrials.gov and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal) for ongoing and recently completed studies. </p> <p> <ul id="CD001347-list-0005"> <li> <p>CENTRAL from inception to 1 April 2016 (<a href="./appendices#CD001347-sec-0127">Appendix 2</a>) </p> </li> <li> <p>MEDLINE from January 1997 to 25 January 2010 (<a href="./appendices#CD001347-sec-0128">Appendix 3</a>) and updated searches from January 2010 to 3 April 2013 and January 2013 to 1 April 2016 (<a href="./appendices#CD001347-sec-0129">Appendix 4</a>) </p> </li> <li> <p>Embase from January 1997 to 27 January 2010 (<a href="./appendices#CD001347-sec-0130">Appendix 5</a>) and updated searches from January 2010 to 3 April 2013 and January 2013 to 1 April 2016 <a href="./appendices#CD001347-sec-0131">Appendix 6</a>) </p> </li> <li> <p>IPA from 1970 to 27 January 2012 (<a href="./appendices#CD001347-sec-0132">Appendix 7</a>) </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a> from inception to March 15 2016 (search terms were (diphosphonates OR biphosphonates) AND osteoporosis) </p> </li> <li> <p><a href="http://www.who.int/ictrp/en/" target="_blank">WHO ICTRP</a> from inception to 15 March 2016 (search terms were bisphosphonates AND osteoporosis) </p> </li> </ul> </p> <p>Differences in search strategy keywords reflect changes in database indexing over time. All languages were included in the search and retrieved. </p> </section> <section id="CD001347-sec-0043"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of relevant review articles and the existing Cochrane Review by the same author (<a href="./references#CD001347-bbs2-0098" title="HomikJ , CranneyA , SheaB , TugwellP , WellsGA , AdachiJ , et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews1999, Issue 1 Art. No.: CD001347. [DOI: 10.1002/14651858.CD001347] ">Homik 1999</a>) to identify any other potentially relevant trials. </p> </section> </section> <section id="CD001347-sec-0044"> <h3 class="title" id="CD001347-sec-0044">Data collection and analysis</h3> <section id="CD001347-sec-0045"> <h4 class="title">Selection of studies</h4> <p>We included RCTs that satisfied the following initial criteria:</p> <p> <ul id="CD001347-list-0006"> <li> <p>prevention or treatment of GIOP;</p> </li> <li> <p>included adults taking a mean steroid dose of 5 mg/day or more;</p> </li> <li> <p>active treatment included any bisphosphonate alone or in combination with calcium or vitamin D; </p> </li> <li> <p>comparator included calcium and/or vitamin D alone or with placebo; and</p> </li> <li> <p>reported relevant outcomes (see <a href="#CD001347-sec-0034">Types of outcome measures</a>). </p> </li> </ul> </p> <p>We excluded trials including people with transplant‐associated steroid use.</p> <p>After fulfilling the above initial criteria, we looked for the following in order for a study to be included in the review: </p> <p> <ul id="CD001347-list-0007"> <li> <p>adequate description of the intervention medications in terms of administration route and schedule; </p> </li> <li> <p>use of standard doses of bisphosphonates (<a href="./references#CD001347-bbs2-0083" title="National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014. ">National Osteoporosis Foundation 2014</a>) in at least one treatment group; and </p> </li> <li> <p>for incident vertebral fractures, radiographic screening was performed routinely, not just in the presence of symptoms, and the criteria used to assess incident fractures were clearly outlined. </p> </li> </ul> </p> <p>Two review authors (JH and JY or JH and CA) independently performed the primary screen of abstracts and full‐text reviews of the eligible reports. Any disagreement on the inclusion of an article was resolved through discussion between the two authors. </p> </section> <section id="CD001347-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JH, CA) independently extracted data from the included trials. In cases of discrepancies in extracted data, the two authors would refer back to the original articles and reach a consensus. For each included trial we recorded the following: </p> <p> <ul id="CD001347-list-0008"> <li> <p>type of trial (method; prevention versus treatment);</p> </li> <li> <p>participant characteristics (age, sex, prevalent vertebral fractures and underlying diseases); </p> </li> <li> <p>mean steroid dose;</p> </li> <li> <p>intervention characteristics for each treatment group;</p> </li> <li> <p>outcome data;</p> </li> <li> <p>fracture assessment criteria.</p> </li> </ul> </p> </section> <section id="CD001347-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JH, JY) independently assessed the methodological quality of the trials included in the primary and secondary analyses using the Cochrane tool for assessing risk of bias (<a href="./references#CD001347-bbs2-0073" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We assessed the following domains: </p> <p> <ul id="CD001347-list-0009"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting; and</p> </li> <li> <p>other bias (i.e. source of funding).</p> </li> </ul> </p> <p>We judged the above criteria using 'Yes': low risk of bias; 'No': high risk of bias; and 'Unclear': lack of information or uncertainty over the potential for bias. The review authors (JH, JY, CA) resolved any disagreements through discussion. </p> </section> <section id="CD001347-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the results of the trials using Review Manager (RevMan) 5.3 statistical software (<a href="./references#CD001347-bbs2-0086" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We conducted pooled analyses for dichotomous variables (incident vertebral and nonvertebral fractures, withdrawals due to adverse events and serious adverse events) using the Mantel‐Haenszel risk ratio (RR) with 95% confidence intervals (CI) (<a href="./references#CD001347-bbs2-0062" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>We analysed continuous data (BMD outcomes) as the mean difference (MD) in BMD between the two treatment groups and the corresponding standard deviation. That is, the per cent change in treatment group BMD minus the per cent change in placebo group BMD. We conducted analysis separately for bone loss at the femoral and lumbar sites, because of the differential effects of corticosteroids on cortical and trabecular bone mass (<a href="./references#CD001347-bbs2-0087" title="RickersH , DedingA , ChristiansenC , RodbroP . Mineral loss in cortical and trabecular bone during high‐dose prednisone treatment. Calcified Tissue International1984;36(3):269–73. ">Rickers 1984</a>). Each trial was weighted taking into account sample size and variance in the outcome variable. </p> <p>To enhance the interpretability of our outcomes we also calculated relative per cent changes; absolute risk differences; and for outcomes with statistically significant differences between intervention groups, the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). These calculations are described below under the heading ‘Summary of findings' table. </p> </section> <section id="CD001347-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for each outcome was the participant. For studies containing more than two intervention groups, multiple pair‐wise comparisons were performed so that the same group of participants was included only once in the meta‐analysis. </p> </section> <section id="CD001347-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>We worked with a biostatistician to compute missing or incomplete data from other available statistics. When studies reported the median change in BMD instead of the mean, we used the median as the best estimate for the mean. </p> <p>When studies did not report standard deviation (SD), we calculated it using either the standard error of the mean (SEM), an exact P value, 95% CI, range, or interquartile range (IQR): </p> <p> <ul id="CD001347-list-0010"> <li> <p>when SEM was reported, we calculated SD as the product of the SEM and the square root of n, where n is the number of subjects in the group; </p> </li> <li> <p>from an exact P value, we calculated SEM as the mean difference between treatment and control groups divided by the z‐stat, where z‐stat was calculated in Microsoft Excel as “=normsinv(1‐p/2)” and then converted to SD using the above formula; </p> </li> <li> <p>from a 95% CI, SEM was calculated as the difference between the upper confidence bound and the lower confidence bound divided by 3.92 and then converted to SD; </p> </li> <li> <p>if using range, we calculated SEM as range divided by the corresponding divisor based on sample size as per <a href="./references#CD001347-bbs2-0097" title="WiebeN , VandermeerB , PlattRW , KlassenTP , MoherD , BarrowmanNJ . A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology2006;59:342‐53. ">Wiebe 2006</a>; </p> </li> <li> <p>if given IQR, we calculated SD as IQR divided by 1.35;</p> </li> <li> <p>where no numerical data were provided, we measured SD from the error bars of a graph;</p> </li> <li> <p>where no error measurement was reported either numerically or graphically, we estimated SD using the mean coefficient of variation of the other trials, weighted by the sample size of each study; </p> </li> <li> <p>where number of participants completing was not reported, the number of participants randomised was used as n. </p> </li> </ul> </p> <p>Where data were imputed or calculated as described above, we reported this in the ‘<a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a>’ tables. </p> </section> <section id="CD001347-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of the data by visual inspection of forest plots and using the I<sup>2</sup> statistic (<a href="./references#CD001347-bbs2-0071" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), for which we interpreted a value greater than 50% as evidence of substantial heterogeneity (<a href="./references#CD001347-bbs2-0091" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). Where substantial heterogeneity was found, we explored the data further using subgroup analyses in an attempt to explore the causes for heterogeneity. </p> <section id="CD001347-sec-0052"> <h5 class="title">'Summary of findings' table</h5> <p>Our major outcomes (incident vertebral and nonvertebral fractures, BMD change after 12 months at the lumbar spine and femoral neck, serious adverse events, withdrawals due to adverse events, and quality of life) are presented in the <a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a> produced using GRADEpro software (<a href="./references#CD001347-bbs2-0069" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 12 June 2015. Hamilton (ON): GRADE Working Group, McMaster University, 2015. ">GRADEpro GDT 2015</a>). This provides information on the certainty of evidence, the magnitude of intervention effect, and the summary of data available for each outcome. The overall certainty of evidence for each outcome was graded (high, moderate, low and very low) using the GRADE approach (<a href="./references#CD001347-bbs2-0093" title="SchünemannH , BrożekJ , GuyattG , OxmanA , (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. ">Schünemann 2013</a>). For dichotomous outcomes with low event rates, we used an optimal information size (OIS) calculator (<a href="./references#CD001347-bbs2-0056" title="Brant , R . Inference for Proportions: Comparing Two Independent Samples. Accessed June 12 2015: stat.ubc.ca/˜rollin/stats/ssize/b2.html, 2014. ">Brant 2014</a>) to assess the precision of data. </p> <p>We included the absolute risk difference and the relative per cent change for each outcome. For statistically significant differences, we also calculated NNTB or NNTH. </p> <p>For dichotomous outcomes we calculated the absolute risk difference using the risk difference (RD) statistic in RevMan 5.3 (<a href="./references#CD001347-bbs2-0086" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) expressed as a percentage; we calculated the relative per cent change as risk ratio (RR) minus one and expressed it as a percentage; we calculated the NNTB/NNTH from the control group event rate and the risk ratio using the Visual RX NNT calculator (<a href="./references#CD001347-bbs2-0058" title="CatesC . Visual Rx Software. 2008. Version Version 1.0 ‐ 3.0. Available from nntonline.net/visualrx/, accessed June 12, 2015. ">Cates 2015</a>). </p> <p>For continuous outcomes, we calculated absolute risk difference as the mean difference between intervention and control group. We calculated the relative difference as the mean difference divided by the mean baseline risk of the control group, calculated in RevMan 5.3 (<a href="./references#CD001347-bbs2-0086" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) using generic inverse variance. We calculated NNTB/NNTH using the Wells calculator software available at Cochrane Musculoskeletal editorial office. There are no published or agreed upon minimal clinically important differences (MCID) for BMD results that we are aware of. In cases where this occurs, the Cochrane Handbook for Systematic Reviews of Interventions recommends using a standardised mean difference (SMD) of 0.5 as an estimate of the minimal clinically important difference (MCID) for each outcome, a rule of thumb representing a moderate effect (<a href="./references#CD001347-bbs2-0092" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.handbook.cochrane.org. ">Schünemann 2011b</a>). It is difficult to ascribe a minimal clinically important difference in terms of per cent change in BMD as a predictable correlation between BMD and fracture risk has not been established in the GIOP setting. BMD changes only account for a small increase in fracture risk (<a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a>; <a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>; <a href="./references#CD001347-bbs2-0096" title="VanStaaTP , LeufkensHGM , CooperC . The Epidemiology of Corticosteroid‐Induced Osteoporosis: a Meta‐analysis. Osteoporosis International2002;13:777‐87. ">Van Staa 2002</a>). The clinical relevance of BMD outcomes is further discussed in '<a href="#CD001347-sec-0112">Summary of main results</a>.' </p> </section> </section> <section id="CD001347-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We analysed both dichotomous and continuous data using a random‐effects model to provide a conservative estimate of effect. </p> </section> <section id="CD001347-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>A subgroup analysis planned a priori compared the treatment effect in prevention trials (bisphosphonates starting within three months of initiating steroids) and in treatment trials (bisphosphonates starting beyond three months of steroid therapy). </p> <p>Where sufficient data existed, we considered post‐hoc subgroup analyses with regard to: </p> <p> <ul id="CD001347-list-0011"> <li> <p>gender and menopausal status;</p> </li> <li> <p>mean steroid dose;</p> </li> <li> <p>prevalent fractures (whether incident fractures occurred in participants with prevalent fractures). </p> </li> </ul> </p> </section> <section id="CD001347-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We planned exploratory sensitivity analyses a priori to evaluate the effect of:</p> <p> <ul id="CD001347-list-0012"> <li> <p>study quality, based on the exclusion of studies that were not blinded; and</p> </li> <li> <p>route of administration of bisphosphonate (oral and parenteral).</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001347-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001347-sec-0056"></div> <section id="CD001347-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD001347-sec-0058"> <h4 class="title">Results of the search</h4> <p>Details of the study selection are presented in <a href="#CD001347-fig-0001">Figure 1</a>. Our initial search of the databases, clinical trials registries and handsearching provided 3934 records after the results were merged and duplicate records removed. A primary screen of the abstracts or protocols resulted in the exclusion of 3347 records. We retrieved the full‐texts of the remaining 587 records and assessed them for eligibility. Based on the full‐text review; 534 were excluded, eight were identified as 'awaiting classification' and six were ongoing trials. The remaining 39 trials underwent data extraction. Another 12 were found to be ineligible and were thus excluded, leaving 27 trials to be included in the review (25 studies from the updated search and two studies from the existing Cochrane Review). Altogether, a total of 27 trials were included in the review, which reported on 3075 participants. </p> <div class="figure" id="CD001347-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001347-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001347-sec-0059"> <h4 class="title">Included studies</h4> <p>Key characteristics of the included trials are contained in the <a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a> tables. </p> <section id="CD001347-sec-0060"> <h5 class="title">Interventions</h5> <p>Most trials used alendronate (n = 9) or cyclic etidronate (n = 8). Other bisphosphonates used include risedronate (n = 2), pamidronate (n = 3), clodronate (n = 3), and ibandronate (n = 2). </p> </section> <section id="CD001347-sec-0061"> <h5 class="title">Underlying diseases</h5> <p>Underlying conditions that required steroid treatment included rheumatological, respiratory, nephrological, gastrointestinal, haematological, dermatological and neurological systemic inflammatory diseases. Most trials (n = 19) included participants with a variety of diseases. Two trials included only participants with rheumatoid arthritis (<a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>); two trials included only participants with systemic lupus erythematosus (<a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>); <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a> reported only on participants with primary biliary cirrhosis; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a> included only participants with chronic obstructive pulmonary disease (COPD) and asthma; <a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a> included only participants with inflammatory bowel disease; and <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a> included only participants with immunobullous skin diseases. </p> </section> <section id="CD001347-sec-0062"> <h5 class="title">Mean steroid dose</h5> <p>Although a minimum mean steroid dose of 5 mg/day was reported in the protocols of our included trials, we found that there was much variability between trials in the actual mean steroid doses used throughout the study period. This was not surprising given the variation in underlying inflammatory diseases and considering that steroid regimes are tapered to fit individual clinical context. </p> <p>Three trials reported a mean steroid dose of 5 to 7.5 mg/day (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>). Ten trials reported a mean steroid dose of approximately 7.5 mg/day (<a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>). Eleven trials reported a mean steroid dose of 10 to 15 mg/day (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). Two trials reported a mean steroid dose of greater than 20 mg/day (<a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>). <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a> was unclear in describing the mean steroid dose used throughout the study period and reported a range of steroid doses that varied between under 7.5 mg/day and 40 mg/day. </p> </section> <section id="CD001347-sec-0063"> <h5 class="title">Prevalent vertebral fractures</h5> <p>Twelve trials had participants with vertebral fractures at baseline (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>). <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a> included prevalent vertebral fractures but excluded participants with symptomatic or two or more radiographic vertebral fractures. Three trials reported no prevalent vertebral fractures in their participants (<a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>), whereas <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a> and <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a> excluded participants with prevalent vertebral fractures. The remaining eight trials did not explicitly state whether or not there were prevalent vertebral fractures (<a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>). </p> </section> <section id="CD001347-sec-0064"> <h5 class="title">Multiple treatment groups</h5> <p>Six of the included trials reported on multiple treatment groups. The standard‐dose arms and control groups were included in the major analyses (<a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>). If a low‐dose arm was reported, we included the studies in a minor outcome analysis of standard‐dose versus low‐dose bisphosphonates (<a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>). One of the multi‐group trials using clodronate reported on groups with dosages of 1600 mg and 2400 mg daily, which were both higher than the current standard and therefore not eligible for the standard‐dose versus low‐dose meta‐analysis (<a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>). </p> <p>Another trial used two distinct pair‐wise comparisons with two independent treatment groups and two independent placebo groups (<a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>). In this study, one pair‐wise comparison involved steroid use of less than six months and the other comparison involved steroid use for longer than six months. Data were entered as two separate trials, as there was no overlap in participants. </p> </section> <section id="CD001347-sec-0065"> <h5 class="title">Prevention versus treatment of GIOP</h5> <p>Thirteen trials involved the prevention of GIOP and 14 trials involved the treatment of GIOP. For trials that had mixed prevention and treatment individuals, we categorised the trial based on whether the majority of participants were considered 'prevention' or 'treatment' as per our criteria described in <a href="#CD001347-sec-0032">Types of participants</a>. <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a> was unclear in describing the type of study so we categorised it as a treatment trial. </p> </section> <section id="CD001347-sec-0066"> <h5 class="title">Outcomes</h5> <section id="CD001347-sec-0067"> <h6 class="title">Incident radiographic vertebral fractures</h6> <p>Twenty‐one trials reported this outcome, 12 trials were included and nine trials excluded from meta‐analysis. </p> <p>Two trials combined fracture data from their 5 mg and 10 mg alendronate treatment arms (<a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>) and although 5 mg daily alendronate was not considered a standard dose, we included these data in the analysis. Of the 12 included studies, seven were prevention trials (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>) and five were treatment trials (<a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>). </p> <p>Since fractures occur at a variable length of time after the onset of osteoporosis, we included trials in which the follow‐up for new fractures occurred between 12 to 24 months, to better ascertain the benefits of bisphosphonates in fracture prevention. We excluded one trial that assessed incident fractures after four years (<a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>) as the timeline differed too greatly from all other trials. Four trials were excluded because they only reported radiographically confirmed symptomatic vertebral fractures and not all participants were screened for vertebral fractures (<a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>). We excluded <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a> because vertebral radiographs were reported on less than half of completing participants, despite a protocol stating routine radiographic screening at baseline and 52 weeks. <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a> did not outline their assessment criteria for fractures and was therefore excluded. One trial reported the number of vertebral fractures rather than the number of participants who experienced fractures and could not be included in the analysis (<a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>). Fracture data from <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a> were not included as this study was a partial cohort from <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>. </p> <section id="CD001347-sec-0068"> <p><b>Fracture Assessment Criteria</b></p> <p>Methods for assessing incident vertebral fractures included quantitative morphometry, semiquantitative grading and a spinal deformity index. Data were analysed regardless of which of the three methods of fracture determination was used. </p> <p><a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a> and its extension study <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a> assessed fractures using both semiquantitative and quantitative methods. For these two trials we included the semiquantitative data as more trials reported incident fractures using this method. </p> <p>Two trials (<a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>) used the quantitative morphometric criteria of <a href="./references#CD001347-bbs2-0075" title="Kiel , D . Assessing vertebral fractures: National Osteoporosis Working Group on Vertebral Fractures. Journal of Bone and Mineral Research1995;10:518–23. ">Kiel 1995</a> and <a href="./references#CD001347-bbs2-0081" title="MeltonLJ3rd , LaneAW , EastellR , O’FallonWM , RiggsBL . Prevalence and incidence of vertebral deformities. Osteoporosis International1993;3:113‐9. ">Melton 1993</a> in which incident fractures were defined as either a reduction in vertebral height of 15% or more (for intact vertebrae at baseline) or 4 mm or more (for fractured vertebrae at baseline). Two other trials (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>) defined incident fractures by quantitative morphometry as a reduction in vertebral height of 20% or 4 mm or more, or both, based on criteria outlined by <a href="./references#CD001347-bbs2-0055" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittM C , et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348:1535‐41. ">Black 1996</a> and <a href="./references#CD001347-bbs2-0067" title="GenantHK , JergasM , PalermoL , NevittM , ValentinRS , BlackD , et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research1996;11(7):984‐96. ">Genant 1996</a>. </p> <p>Six trials used semiquantitative grading with a minimum reduction in vertebral height of 20% as criteria for incident vertebral fractures (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>) as per <a href="./references#CD001347-bbs2-0066" title="GenantHK , WuCY , VanKuijkC , NevittMC . Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research1993;8(9):1137‐48. ">Genant 1993</a> and <a href="./references#CD001347-bbs2-0095" title="VanKuijkC , GenantHK . Radiological aspects. In: RiggsBL , MeltonLJIII editor(s). Osteoporosis: etiology, diagnosis, and management. 2nd Edition. Philadelphia: Lippincott‐Raven, 1995:249‐73. ">Van Kujik 1995</a> and one trial used or a reduction in height of 15% or more (<a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>) according to <a href="./references#CD001347-bbs2-0076" title="KleerekoperM , ParfittAM , EllisBI . Measurements of vertebral fracture rates in osteoporosis. Proceedings of the Copenhagen International Symposium on Osteoporosis. Copenhagen: AalbergStiftsbogtrykkeri, June 3‐8, 1984:103‐109. ">Kleerekoper 1984</a>. </p> <p>Two trials used the <a href="./references#CD001347-bbs2-0082" title="MinneHW , LeidigG , WusterC , SiromachkostovL , BaldaufG , BickelR , et al. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Mineral1988;3:335–49. ">Minne 1988</a> spinal deformity index (<a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>), which determines the extent of vertebral compression by comparison of the actual vertebral body height to the presumable original height. </p> </section> </section> <section id="CD001347-sec-0069"> <h6 class="title">Incident radiographic nonvertebral fractures</h6> <p>Thirteen trials reported this outcome, nine trials were included and four trials excluded from meta‐analysis. </p> <p>Fracture sites included but were not limited to the hip, wrist, forearm, and midfoot. No atypical femur fractures were reported in any of the included trials. We reported all nonvertebral fracture data together as the majority of trials did not include complete information on specific fracture sites. Three trials reported nonvertebral fractures but provided the total number of fractures rather than the number of participants suffering from fractures and were therefore not included in the analysis (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>). Another trial reported nonvertebral fractures occurring after four years and was not included in the analysis (<a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>). Protocols for assessing nonvertebral fractures were typically not stated in study procedures. We assumed all nonvertebral fractures were self‐reported symptomatic ones. </p> </section> <section id="CD001347-sec-0070"> <h6 class="title">BMD data</h6> <section id="CD001347-sec-0071"> <p><b>12 months (lumbar spine)</b></p> <p>Twenty‐six trials reported this outcome, 23 trials were included and three trials excluded from meta‐analysis. </p> <p>Two trials (<a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>) reported data that were insufficient for inclusion in the lumbar spine analysis. <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a> reported BMD using T scores and was therefore not included in the analysis. </p> </section> <section id="CD001347-sec-0072"> <p><b>12 months (femoral neck)</b></p> <p>Twenty‐three trials reported this outcome, 18 trials were included and five trials excluded from meta‐analysis. </p> <p>Reported data from <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a> and <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a> were insufficient for inclusion in the femoral neck analysis. <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a> reported “no change” in femoral neck BMD without providing any numerical data and was therefore not included in the femoral neck analysis. <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a> reported BMD using T scores and was therefore not included in the femoral neck analysis. </p> </section> <section id="CD001347-sec-0073"> <p><b>18 to 24 months</b></p> <p>Nine trials reported BMD outcomes at 18 to 24 months at both the lumbar spine and femoral neck and were included in separate analyses. One multi‐arm trial used two distinct pair‐wise comparisons with two independent treatment groups and two independent placebo groups (<a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>). In this study, one pair‐wise comparison involved steroid‐use of less than six months and the other comparison involved steroid‐use greater than six months. The data were entered as two separate trials, therefore each analysis has 10 pair‐wise comparisons. </p> </section> <section id="CD001347-sec-0074"> <p><b>Low‐dose versus standard‐dose bisphosphonates</b></p> <p>Five trials included multi‐group trials with head‐to‐head comparisons of standard‐dose versus low‐dose bisphosphonates. All five trials reported on lumbar spine BMD and were included in this meta‐analysis. Four trials reported on femoral neck BMD and were all included in the analysis on femoral neck BMD. </p> </section> </section> <section id="CD001347-sec-0075"> <h6 class="title">Serious adverse events</h6> <p>Nineteen trials reported this outcome, 15 trials were included and four were excluded from the meta‐analysis. </p> <p>Serious adverse events were most commonly defined as any event requiring hospitalisation, that was life‐threatening or fatal. One trial that we included defined serious adverse events as any event that rendered a patient incapable of performing normal activities (<a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>). Few included trials provided details on the types of serious adverse events that occurred (see <a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a> for further details). Five trials only reported deaths and did not specify the occurrence of other forms of serious adverse events (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>) though we still included these trials in the analysis. The protocol for assessing adverse events was not clearly stated in seven of the trials included in this analysis (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>). </p> <section id="CD001347-sec-0076"> <p><b>Deaths</b></p> <p>From the included trials, nine deaths were reported in the experimental groups (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>) and five deaths were reported in the control groups (<a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>). In none of these cases did the study authors consider the deaths to be related to the study or placebo drugs. See <a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a> for further details. </p> <p>Data from <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a> were not included as it was an extension trial of <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>, which provided more complete data. <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a> and <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a> each reported deaths but did not specify from which treatment group they occurred and were therefore not included in the analysis. </p> </section> </section> <section id="CD001347-sec-0077"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Twenty‐one trials reported this outcome, 15 trials were included and six trials were excluded from meta‐analysis. </p> <p>For this analysis we included withdrawals due to all adverse events regardless of their association to either the control or drug of study. We did not include death as a withdrawal due to an adverse event. See <a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a> for further details on types of adverse events leading to study withdrawal. </p> <p>Four trials did not specify which treatment groups the withdrawals came from (<a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>) and were therefore excluded from the analysis. Another trial did not provide numerical data on the withdrawals (<a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>) and could not be included. Data from <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a> were not included as it was an extension trial of <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>. </p> </section> <section id="CD001347-sec-0078"> <h6 class="title">Quality of life</h6> <p>This outcome was not assessed by any of the trials.</p> </section> </section> </section> <section id="CD001347-sec-0079"> <h4 class="title">Excluded studies</h4> <p>From our search of the databases, clinical trials registries and handsearching, we excluded 534 of the 587 articles that underwent full‐text review. The main reason for exclusion was not being an RCT (n = 330). We excluded 33 trials as they involved transplant‐associated steroid use. See <a href="#CD001347-fig-0001">Figure 1</a> for complete details. During data extraction from 39 studies, we excluded 11 for using only non‐standard bisphosphonate doses (<a href="./references#CD001347-bbs2-0028" title="BenucciM , SaviolaG , BaiardiP , Abdi‐AliL , PovinoMR , DolentiS , et al. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low‐dose glucocorticoids. Clinical and Experimental Rheumatology2009;27(4):567‐73. ">Benucci 2009</a>; <a href="./references#CD001347-bbs2-0029" title="FujiiN , HamanoT , MikamiS , NagasawaY , IsakaY , MoriyamaT , et al. Risedronate, an effective treatment for glucocorticoid‐induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS‐CKD). Nephrology Dialysis Transplantation2007;22:1601‐7. ">Fujii 2006</a>; <a href="./references#CD001347-bbs2-0030" title="JinnouchiY . Efficacy of intermittent etidronate therapy for corticosteroid‐induced osteoporosis in patients with diffuse connective tissue disease. Kurume Medical Journal2000;47:219‐24. ">Jinnouchi 2000</a>; <a href="./references#CD001347-bbs2-0031" title="KikuchiY , ImakiireT , YamadaM , SaigusaT , HyodoT , KushiyamaT , et al. Effect of risedronate on high‐dose corticosteroid‐induced bone loss in patients with glomerular disease. Nephrology Dialysis Transplantation2007;22:1593‐600. ">Kikuchi 2006</a>; <a href="./references#CD001347-bbs2-0032" title="KitazakiS , MitsuyamaK , MasudaJ , HaradaK , YamasakiH , KuwakiK , et al. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid‐associated osteoporosis in patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2009;29(4):424‐30. ">Kitazaki 2008</a>; <a href="./references#CD001347-bbs2-0033" title="NakayamadaS , OkadaY , SaitoK , TanakaY . Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. Journal of Rheumatology2004;31:163‐6. ">Nakayamada 2004</a>; <a href="./references#CD001347-bbs2-0034" title="OkadaY , NawataM , NakayamadaS , SaitoK , TanakaY . Alendronate protects premenopausal women from bone loss and fracture associated with high‐dose glucocorticoid therapy. Journal of Rheumatology2008;35:2249‐54. ">Okada 2008</a>; <a href="./references#CD001347-bbs2-0035" title="SatoS , OhosoneY , SuwaA , YasuokaH , NojimaT , FujiiT , et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow up. Journal of Rheumatology2003;30:2673‐9. ">Sato 2003</a>; <a href="./references#CD001347-bbs2-0036" title="TakedaS , KaneokaH , SaitoT . Effect of alendronate on glucocorticoid‐induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Modern Rheumatology2008;18(3):271‐6. ">Takeda 2008</a>; <a href="./references#CD001347-bbs2-0037" title="TakeiT , ItabashiM , TsukadaM , SugiuraH , MoriyamaT , KojimaC , et al. Risedronate therapy for the prevention of steroid‐induced osteoporosis in patients with minimal‐change nephrotic syndrome. Internal Medicine2010;49(19):2065‐70. ">Takei 2010</a>; <a href="./references#CD001347-bbs2-0038" title="ToukapAN , DepresseuxG , DevogelaerJP , HoussiauFA . Oral pamidronate prevents high‐dose glucocorticoid‐induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus2005;14:517‐20. ">Toukap 2005</a>), and we categorised <a href="./references#CD001347-bbs2-0046" title="OzoranK , YildirimM , ÖnderM , SivasF , InanirA . The bone mineral density effects of calcitonin and alendronate combined therapy in patients with rheumatoid arthritis. Asia Pacific League of Associations for Rheumatology Journal of Rheumatology2007;10:17‐22. ">Ozoran 2007</a> as 'awaiting classification' pending data clarification from the study authors due to insufficient reporting of relevant outcome data. We have included the references of the 12 trials that we excluded during data extraction as they did meet our initial criteria for inclusion and may still be of relevance (details in <a href="./references#CD001347-sec-0143" title="">Characteristics of excluded studies</a>). In addition, eight trials were deemed to be 'awaiting classification' (details in <a href="./references#CD001347-sec-0144" title="">Characteristics of studies awaiting classification</a>). Of these, four trials identified from trials registers were completed but with no publications available and four trials were published as articles in Japanese with no English versions available (<a href="./references#CD001347-bbs2-0039" title="ImanishiY , NishizawaY . Activate form vitamin D3 or bisphosphonate in glucocorticoid‐induced osteoporosis. Clinical Calcium2006;16(11):1844‐50. ">Imanishi 2006</a>; <a href="./references#CD001347-bbs2-0040" title="NakamuraT , MaekawaS , MorinobuS , MorinobuA , KoshibaM , YamauchiM , et al. The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis. Ryumachi2002;42(4):666‐75. ">Nakamura 2002</a>; <a href="./references#CD001347-bbs2-0045" title="Okazaki , R . Pharmacological treatment of other types of secondary osteoporosis. Nippon Rinsho ‐ Japanese Journal of Clinical Medicine2015;73(10):1740‐5. ">Okazaki 2015</a>; <a href="./references#CD001347-bbs2-0047" title="SuzukiY . Glucocorticoid‐induced osteoporosis. Nippon Rinsho ‐ Japanese Journal of Clinical Medicine2015;73(10):1733‐39. ">Suzuki 2015</a>). We are currently awaiting the translation of these four trials and will update the review once information is available. Finally, we identified six ongoing trials that may be of relevance to this review (details in <a href="./references#CD001347-sec-0145" title="">Characteristics of ongoing studies</a>). </p> <p>The existing Cochrane Review included 13 trials and of these, only two trials were included in this review (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>). Five trials were conference abstracts that have been subsequently published and the full publications were included (<a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>). We excluded four trials because they were not RCTs. We excluded one trial because it measured BMD by computerised tomography (CT) instead of DEXA. Another trial from the original review reported outcome measurements at six months only. We decided that this time point was not clinically significant and not analysed in this review update, therefore we excluded this trial. </p> </section> </section> <section id="CD001347-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>Detailed results of this assessment are found in a table attached to the <a href="./references#CD001347-sec-0142" title="">Characteristics of included studies</a> table and are summarised below in <a href="#CD001347-fig-0002">Figure 2</a> and <a href="#CD001347-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001347-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001347-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001347-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001347-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001347-sec-0081"> <h4 class="title">Allocation</h4> <p>Four studies clearly described random sequence generation methods and allocation concealment and were at low risk for selection bias (<a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>). </p> <p>Eighteen studies did not provide details on random sequence generation methods or allocation concealment and so were at unclear risk for selection bias (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>). </p> <p>Five studies were at low risk of bias for randomisation as they provided clear descriptions of random sequence generation but were considered to have unclear risk of bias for allocation concealment, as no allocation details were provided (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). </p> </section> <section id="CD001347-sec-0082"> <h4 class="title">Blinding</h4> <p>Twelve studies provided adequate detail on blinding of participants, personnel and outcome assessment, so were at low risk for performance and detection bias (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>) </p> <p>Two studies did not provide details on blinding of participants, personnel or outcome assessors, so were at unclear risk for performance and detection bias (<a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>). </p> <p>Six studies provided adequate detail on blinding of participants/personnel but did not mention blinding of outcome assessment so were at low risk for performance bias and unclear risk for detection bias (<a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>). </p> <p>Three studies had explicit and appropriate outcome assessment blinding, but clearly stated that participants/personnel were not blinded or were not placebo‐controlled, so were at high risk for performance bias and low risk for detection bias (<a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). </p> <p>Four studies had insufficient participant/personnel blinding and did not provide clear details on outcome assessment blinding, so were at high risk for performance bias and unclear risk for detection bias (<a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>). </p> </section> <section id="CD001347-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐one studies had sufficiently complete outcome data, adequately addressed reasons for dropout, with dropout similar between both groups, so were at low risk for attrition bias (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>). </p> <p>Three studies did not clearly address the reasons for participant dropout, so were at unclear risk for attrition bias (<a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a> had low dropout and addressed reasons for dropout but only screened vertebral fractures radiographically in 13 of 28 completing participants. No explanation was provided for the low yield of vertebral radiographs so this study was at unclear risk for attrition bias. </p> <p><a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a> had 31% of participants that did not complete the first year and only 23 of 38 completing participants were screened for radiographic vertebral fractures. <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a> had 30% of participants that did not complete the study with the main reason being that they were unavailable for follow‐up. Both these studies were at high risk for attrition bias. </p> </section> <section id="CD001347-sec-0084"> <h4 class="title">Selective reporting</h4> <p>Twenty‐five studies reported all outcomes that were listed in the methods section and were therefore considered to be at low risk for reporting bias (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). </p> <p><a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a> had no mention of adverse events. <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a> took spinal radiographs to validate DEXA measurements only, not as an outcome. Both these studies were at unclear risk for reporting bias. </p> </section> <section id="CD001347-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>Eighteen studies were judged to be at low risk as no other sources of bias were apparent (<a href="./references#CD001347-bbs2-0001" title="AbitbolV , BriotK , RouxC , RoyC , SeksikP , CharachonA , et al. A double‐blind placebo‐controlled study of intravenous clodronate for prevention of steroid‐induced bone loss in inflammatory bowel disease. Clinical Gastroenterology &amp; Hepatology2007;5:1184‐9. ">Abitbol 2007</a>; <a href="./references#CD001347-bbs2-0004" title="BoutsenY , JamartJ , EsselinckxW , StoffelM , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcified Tissue International1997;61:266‐71. ">Boutsen 1997</a>; <a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0007" title="CortetB , HachullaE , BartonI , BonvoisinB , RouxC . Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid‐induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Revue du Rhumatisme (English Edition)1999;66:214‐9. ">Cortet 1999</a>; <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a>; <a href="./references#CD001347-bbs2-0010" title="GeusensP , DequekerJ , VanhoofJ , StalmansR , BoonenS , JolyJ , et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Annals of the Rheumatic Diseases1998;57:724‐7. ">Geusens 1998</a>; <a href="./references#CD001347-bbs2-0012" title="HerralaJ , PuolijokiH , LiippoK , RaitioM , ImpivaaraO , TalaE , et al. Clodronate is effective in preventing corticosteroid‐induced bone loss among asthmatic patients. Bone1998;22:577‐82. ">Herrala 1998</a>; <a href="./references#CD001347-bbs2-0013" title="JenkinsEA , Walker‐BoneKE , WoodA , McCraeFC , CooperC , CawleyMI . The prevention of corticosteroid‐induced bone loss with intermittent cyclical etidronate. Scandinavian Journal of Rheumatology1999;28:152‐6. ">Jenkins 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0015" title="LiEK , ZhuTY , HungVY , KwokAW , LeeVW , LeeKK , et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long‐term glucocorticoid. Arthritis Research &amp; Therapy2010;12(5):R198. ">Li 2010</a>; <a href="./references#CD001347-bbs2-0016" title="PittP , LiF , ToddP , WebberD , PackS , MonizC . A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long‐term oral corticosteroid treatment. Thorax1998;53:351‐6. ">Pitt 1998</a>; <a href="./references#CD001347-bbs2-0018" title="RouxC , OrienteP , LaanR , HughesRA , IttnerJ , GoemaereS , et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group. Journal of Clinical Endocrinology &amp; Metabolism1998;83:1128‐33. ">Roux 1998</a>; <a href="./references#CD001347-bbs2-0019" title="SaadatiN , RajabianR . The effect of bisphosphonate on prevention of glucocorticoid‐induced osteoporosis. Iranian Red Crescent Medical Journal2008;10(1):8‐11. ">Saadati 2008</a>; <a href="./references#CD001347-bbs2-0022" title="SkingleSJ , MooreDJ , CrispAJ . Cyclical etidronate increases lumbar spine bone density in patients on long‐term glucocorticosteroid therapy. International journal of clinical practice1997;51:364‐7. ">Skingle 1997</a>; <a href="./references#CD001347-bbs2-0023" title="StochSA , SaagKG , GreenwaldM , SebbaAI , CohenS , VerbruggenN , et al. Once‐weekly oral alendronate 70 mg in patients with glucocorticoid‐induced bone loss: a 12‐month randomized, placebo‐controlled clinical trial. Journal of Rheumatology2009;36:1705‐14. ">Stoch 2009</a>; <a href="./references#CD001347-bbs2-0024" title="TeeSI , YosipovitchG , ChanYC , ChuaSH , KohET , ChanYH , et al. Prevention of glucocorticoid‐induced osteoporosis in immunobullous diseases with alendronate: a randomized, double‐blind, placebo‐controlled study. Archives of Dermatology2012;148(3):307‐14. ">Tee 2012</a>; <a href="./references#CD001347-bbs2-0025" title="VanOffelJF , SchuerweghAJ , BridtsCH , BrackePG , StevensWJ , DeClerckLS . Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clinical &amp; Experimental Rheumatology2001;19:13‐20. ">Van Offel 2001</a>; <a href="./references#CD001347-bbs2-0026" title="WolfhagenFH , VanBuurenHR , DenOudenJW , HopWC , VanLeeuwenJP , SchalmSW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. A prospective, controlled pilot study. Journal of Hepatology1991;26:325‐30. ">Wolfhagen 1997</a>). Five studies were also rated as low risk and had pharmaceutical industry contribution that was limited to supplying the study drug or providing grants, with no industry authorship (<a href="./references#CD001347-bbs2-0002" title="AdachiJD , BensenWG , BrownJ , HanleyD , HodsmanA , JosseR , et al. Intermittent etidronate therapy to prevent corticosteroid‐induced osteoporosis. New England Journal of Medicine1997;337(6):382‐7. ">Adachi 1997</a>; <a href="./references#CD001347-bbs2-0008" title="DeNijsRN , JacobsJW , LemsWF , LaanRF , AlgraA , HuismanAM , et al. Alendronate or alfacalcidol in glucocorticoid‐induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178‐85; PMID: 17557758]. New England Journal of Medicine2006;355:675‐84. ">De Nijs 2006</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>; <a href="./references#CD001347-bbs2-0021" title="SambrookPN , KotowiczM , NashP , StylesCB , NaganathanV , Henderson‐BriffaKN , et al. Prevention and treatment of glucocorticoid‐induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of Bone &amp; Mineral Research2003;18:919‐24. ">Sambrook 2003</a>; <a href="./references#CD001347-bbs2-0027" title="YeapSS , FauziAR , KongNC , HalimAG , SoehardyZ , RahimahI , et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid‐treated premenopausal patients with systemic lupus erythematosus. Journal of Rheumatology2008;35:2344‐7. ">Yeap 2008</a>). </p> <p>Four studies were rated as having an unclear risk of bias due to other sources. Two studies had industry authorship (<a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0011" title="HakalaM , KrögerH , VallealaH , Hienonen‐KempasT , Lehtonen‐VeromaaM , HeikkinenJ , et al. Once‐monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12‐month, randomized, double‐blind, placebo‐controlled trial. Scandinavian Journal of Rheumatology2012;41(4):260‐6. ">Hakala 2012</a>); and <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a> reported industry involvement in the design, implementation and analysis of the trial. We rated <a href="./references#CD001347-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44:202‐11. ">Adachi 2001</a> as unclear because it was an extension study, which has the potential risk of unblinding. </p> </section> </section> <section id="CD001347-sec-0086"> <h3 class="title" id="CD001347-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD001347-tbl-0001"><b>Summary of findings for the main comparison</b> Bisphosphonates versus control for adults with GIOP</a> </p> <section id="CD001347-sec-0087"> <h4 class="title">Benefits</h4> <section id="CD001347-sec-0088"> <h5 class="title">Incident radiographic vertebral fractures</h5> <p>Twelve trials (1343 participants) reported the number of participants with new vertebral fractures. We combined symptomatic and asymptomatic fractures. In this analysis 46/597 (or 77 per 1000) people experienced new vertebral fractures in the control group compared with 31/746 (or 44 per 1000; range 27 to 70) in the bisphosphonate group. The resulting RR was statistically significant at 0.57 (95% CI 0.35 to 0.91) (<a href="./references#CD001347-fig-0004" title="">Analysis 1.1</a>) signifying a relative per cent improvement of 43% (95% CI 9% to 65% better) with bisphosphonates; an absolute increased benefit of 2% fewer people experiencing fractures (95% CI 5% fewer to 1% more); and NNTB of 31 (95% CI 20 to 145) meaning that approximately 31 people would need to be treated with bisphosphonates to prevent new vertebral fractures in one person (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). There was no statistical heterogeneity in the incident vertebral fracture analysis (I<sup>2</sup> = 0%). Overall, there was high‐certainty evidence for a reduction in new vertebral fractures with bisphosphonates. </p> </section> <section id="CD001347-sec-0089"> <h5 class="title">Incident radiographic nonvertebral fractures</h5> <p>In the analysis of nine trials (1245 participants), 30/546 (or 55 per 1000) people experienced new nonvertebral fractures in the control group compared with 29/699 (or 42 per 1000; range 25 to 69) in the bisphosphonate group. The resulting RR was 0.79 (95% CI 0.47 to 1.33) although this was not statistically significant (<a href="./references#CD001347-fig-0005" title="">Analysis 1.2</a>). There was a relative per cent improvement of 21% (95% CI 33% worse to 53% better) with bisphosphonates; an absolute increased benefit of 1% fewer people experiencing fractures (95% CI 4% fewer to 1% more); NNTB not applicable as results were not statistically significant (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). There was no statistical heterogeneity in the nonvertebral fracture analysis (I<sup>2</sup> = 0%). Overall, there was low‐certainty evidence that bisphosphonates may make little or no difference in the reduction of new nonvertebral fractures (downgraded for risk of bias and imprecision). </p> </section> <section id="CD001347-sec-0090"> <h5 class="title">Per cent change in lumbar spine BMD</h5> <p><b>Bisphosphonate treatment up to 12 months</b> </p> <p>In the analysis of 23 trials (2042 participants), bisphosphonate use resulted in a statistically significant MD of 3.50% (95% CI 2.90% to 4.10%) (<a href="./references#CD001347-fig-0006" title="">Analysis 2.1</a>) representing an absolute benefit with BMD 3.5% higher with bisphosphonates as compared to calcium or vitamin D alone (95% CI 2.90% to 4.10% higher); a relative per cent improvement of 1.1% (95% CI 0.91% to 1.29% better); NNTB 3 (95% CI 2 to 3) meaning that approximately three people would need to be treated with bisphosphonates over 12 months in order to see a minimally important difference in lumbar spine BMD in one person (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). There was substantial heterogeneity among these trials (I<sup>2</sup> = 70%) that we found was adequately explained through subgroup and sensitivity analyses shown below. Overall, there was moderate‐certainty evidence of a clinically important increase in lumbar spine BMD with bisphosphonates (downgraded for indirectness). </p> <p><b>Bisphosphonate treatment 18 to 24 months</b> </p> <p>In the analysis of nine trials (10 treatment groups) reporting on 802 participants, bisphosphonate use resulted in a statistically significant 5.49% (95% CI 3.47% to 7.51%) increase in BMD as compared to treatment with calcium or vitamin D alone (<a href="./references#CD001347-fig-0010" title="">Analysis 2.5</a>). There was substantial heterogeneity in this analysis (I<sup>2</sup> = 91%). We removed one trial that differed from the others by using IM bisphosphonates in a female‐only population, which reduced the I<sup>2</sup> statistic to 41% (result not shown). </p> </section> <section id="CD001347-sec-0091"> <h5 class="title">Per cent change in femoral neck BMD</h5> <p><b>Bisphosphonate treatment up to 12 months</b> </p> <p>Results from 18 trials (1665 participants) showed that bisphosphonate use resulted in a statistically significant MD of 2.06% (95% CI 1.45 to 2.68) (<a href="./references#CD001347-fig-0013" title="">Analysis 3.1</a>) representing an absolute benefit with BMD 2.06% higher in the bisphosphonate group as compared to treatment with calcium or vitamin D alone (95% CI 1.45% to 2.68% higher); a relative per cent improvement of 1.29% (95% CI 0.91% to 1.69% better); NNTB 5 (95% CI 4 to 7) meaning that approximately five people would need to be treated with bisphosphonates over 12 months in order to see a minimally important difference in femoral neck BMD in one person (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). The heterogeneity among these trials was not substantial (I<sup>2</sup> = 34%). Overall, there was moderate‐certainty evidence of a clinically important increase in femoral neck BMD with bisphosphonates (downgraded for indirectness) . </p> <p><b>Bisphosphonate treatment 18 to 24 months</b> </p> <p>Analysis of nine trials (10 treatment groups) reporting on 802 participants showed that bisphosphonate use resulted in a statistically significant 3.28% (95% CI 1.70% to 4.87%) increase in BMD as compared to treatment with calcium or vitamin D alone (<a href="./references#CD001347-fig-0017" title="">Analysis 3.5</a>). There was substantial heterogeneity among the trials in this analysis (I<sup>2</sup> = 83%). One trial differed by using intramuscular (IM) bisphosphonates and another trial had a lower mean participant age, however removing single trials did not appreciably alter the heterogeneity. </p> </section> <section id="CD001347-sec-0092"> <h5 class="title">Quality of life</h5> <p>Quality of life was not assessed by any of the trials.</p> </section> <section id="CD001347-sec-0093"> <h5 class="title">Per cent change in BMD at 12 months with low‐dose versus standard‐dose bisphosphonates</h5> <section id="CD001347-sec-0094"> <h6 class="title">Lumbar spine</h6> <p>Head‐to‐head analysis of five trials (642 participants) resulted in a MD of 0.95% (95% CI 0.37% to 1.53%) that was statistically significant (<a href="./references#CD001347-fig-0009" title="">Analysis 2.4</a>). There was no statistical heterogeneity in this analysis (I<sup>2</sup> = 0%) </p> </section> <section id="CD001347-sec-0095"> <h6 class="title">Femoral neck</h6> <p>Head‐to‐head analysis of four trials (542 participants) showed a MD of 0.74% (95% CI ‐0.42% to 1.90%) that did not reach statistical significance with substantial heterogeneity among trials (I<sup>2</sup> = 54%) (<a href="./references#CD001347-fig-0016" title="">Analysis 3.4</a>). </p> </section> </section> </section> <section id="CD001347-sec-0096"> <h4 class="title">Harms</h4> <section id="CD001347-sec-0097"> <h5 class="title">Serious adverse events</h5> <p>Fifteen trials (1703 participants) reported on serious adverse events with 131/811 (or 162 per 1000) people experiencing serious adverse events in the control group compared to 136/892 (or 147 per 1000; range 120 to 181) in the bisphosphonate group. The RR for serious adverse events in the bisphosphonate group was 0.91 (95% CI 0.74 to 1.12) (<a href="./references#CD001347-fig-0019" title="">Analysis 4.1</a>); an absolute increased harm of 0% more serious adverse events (95% CI 2.00% fewer to 2.00% more); a relative per cent change 9% improvement (95% CI 12% worse to 26% better); NNTH not applicable as there was no statistically significant difference (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). There was no statistical heterogeneity in the analysis on serious adverse events (I<sup>2</sup> = 0%). Overall, there was low‐certainty evidence (downgraded for imprecision and risk of bias) that bisphosphonates may make little or no difference in the number of serious adverse events. </p> </section> <section id="CD001347-sec-0098"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Fifteen trials (1790 participants) reported withdrawals due to adverse events. Not all adverse events were listed, but in those trials that did have information, the most common adverse events were upper gastrointestinal symptoms and musculoskeletal pain. In this analysis, 63/866 (or 73 per 1000) people withdrew in the control group compared to 76/924 (or 77 per 1000; range 56 to 107) in the bisphosphonate group. The RR for withdrawals due to adverse events in the bisphosphonate group was not statistically significant at 1.06 (95% CI 0.77 to 1.47) (<a href="./references#CD001347-fig-0020" title="">Analysis 4.2</a>); an absolute increased harm of 1% more withdrawals with bisphosphonates (95% CI 1% fewer to 3% more); a relative per cent change 6% worse (95% CI 47% worse to 23% better); NNTH not applicable as there was no statistically significant difference between groups (<a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a>). There was no substantial heterogeneity in the withdrawals due to adverse events analysis (I<sup>2</sup> = 2%). Overall, there was low‐certainty evidence (downgraded for imprecision and risk of bias) that bisphosphonates may make little or no difference in the number of withdrawals due to adverse events. </p> </section> </section> <section id="CD001347-sec-0099"> <h4 class="title">Subgroup analyses</h4> <section id="CD001347-sec-0100"> <h5 class="title">Prevention and treatment studies</h5> <p>A pre‐specified subgroup analysis was used to analyse separately prevention and treatment effects in trials reporting on BMD at the lumbar spine and femoral neck at 12 months. </p> <section id="CD001347-sec-0101"> <h6 class="title">Lumbar spine</h6> <p>In the prevention analysis (12 trials, 930 participants) bisphosphonate use resulted in an increase in BMD of 3.92% (95% CI 2.90% to 4.94%) as compared to treatment with calcium or vitamin D alone (<a href="./references#CD001347-fig-0006" title="">Analysis 2.1</a>). In the treatment analysis (11 trials, 1112 participants), bisphosphonate use resulted in an increase in BMD of 3.19% (95% CI 2.64% to 3.73%) as compared to treatment with calcium or vitamin D alone (<a href="./references#CD001347-fig-0006" title="">Analysis 2.1</a>). Both were statistically significant. There was substantial heterogeneity among the studies in the prevention analysis (I<sup>2</sup> = 80%) but not the treatment analysis (I<sup>2</sup> = 16%). A sub‐subgroup analysis was done for the prevention analysis to separate trials using parenteral and oral bisphosphonates (<a href="./references#CD001347-fig-0011" title="">Analysis 2.6</a>). This appears to explain the significant heterogeneity in the prevention analysis. There were no parenteral bisphosphonates used in treatment trials. </p> </section> <section id="CD001347-sec-0102"> <h6 class="title">Femoral neck</h6> <p>In the prevention analysis (10 trials, 751 participants), bisphosphonate use resulted in a statistically significant increase in BMD of 2.79% (95% CI 1.99% to 3.59%) as compared to treatment with calcium or vitamin D alone (<a href="./references#CD001347-fig-0013" title="">Analysis 3.1</a>). In the treatment analysis (eight trials, 914 participants), the increase in BMD was 1.53% (95% CI 0.73% to 2.33%) (<a href="./references#CD001347-fig-0013" title="">Analysis 3.1</a>). Both were statistically significant. There was no substantial heterogeneity in either the prevention or treatment analyses (I<sup>2</sup> = 0% and 44%, respectively). </p> </section> </section> <section id="CD001347-sec-0103"> <h5 class="title">Gender and menopausal status</h5> <p>Fracture data were not broken down by gender and menopausal status in the individual trials included in our analysis and therefore post‐hoc subgroup analyses were not possible for fracture outcomes. Sufficient data on BMD at the lumbar spine and femoral neck at 12 months were available to analyse subgroups of gender and menopausal status (men, premenopausal women, postmenopausal women). Please see <a href="./references#CD001347-fig-0012" title="">Analysis 2.7</a> and <a href="./references#CD001347-fig-0018" title="">Analysis 3.6</a> for full details on results. </p> </section> <section id="CD001347-sec-0104"> <h5 class="title">Mean steroid dose</h5> <p>In the vertebral fracture, nonvertebral fracture and 12 months BMD outcomes, <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a> was the only trial to use high‐dose steroids (greater or equal to 20 mg/day). </p> </section> <section id="CD001347-sec-0105"> <h5 class="title">Prevalent fractures</h5> <p>No trials reported outcome data separately for those participants with and without a prevalent fracture. </p> </section> </section> <section id="CD001347-sec-0106"> <h4 class="title">Sensitivity analyses</h4> <section id="CD001347-sec-0107"> <h5 class="title">Risk of bias</h5> <p>To analyse the effect of study quality, based on the exclusion of non‐blinded trials (high risk for performance or detection bias) we performed a sensitivity analysis. Sensitivity analyses excluding high‐risk trials for the outcomes of incident vertebral fractures; incident nonvertebral fractures; BMD at the lumbar spine and femoral neck after 12 months and 18 to 24 months; serious adverse events; withdrawals due to adverse events; BMD using low‐ versus standard‐dose bisphosphonates did not appreciably change the effect sizes and did not resolve heterogeneity among trials (results not shown). </p> </section> <section id="CD001347-sec-0108"> <h5 class="title">Route of administration</h5> <p>We performed a sensitivity analysis based on route of administration. We analysed trials using oral bisphosphonates separately from those using parenteral bisphosphonates. The trials reported BMD data at the lumbar spine and femoral neck at 12 months. </p> <section id="CD001347-sec-0109"> <h6 class="title">Lumbar spine</h6> <p>At the lumbar spine, pooled analysis of 18 trials (1767 participants) using oral treatments showed a statistically significant result with MD 3.25% (95% CI 2.88% to 3.63%) (<a href="./references#CD001347-fig-0007" title="">Analysis 2.2</a>). </p> <p>Analysis of five trials (275 participants) using parenteral treatments had a statistically significant MD 5.12% (95% CI 2.35% to 7.89%) at the lumbar spine (<a href="./references#CD001347-fig-0008" title="">Analysis 2.3</a>). There was no statistical heterogeneity in the oral analysis (I<sup>2</sup> = 0%) but heterogeneity was substantial in the lumbar spine parenteral treatment analysis (I<sup>2</sup> = 90%). </p> </section> <section id="CD001347-sec-0110"> <h6 class="title">Femoral neck</h6> <p>At the femoral neck, analysis of 15 trials (1574 participants) using oral administration had a statistically significant MD 1.92% (95% CI 1.31% to 2.53%) (<a href="./references#CD001347-fig-0014" title="">Analysis 3.2</a>). </p> <p>Analysis of three trials (91 participants) using parenteral therapy was also statistically significant with MD 4.56% (95% CI 2.07% to 7.05%) (<a href="./references#CD001347-fig-0015" title="">Analysis 3.3</a>). There was no substantial heterogeneity in either the oral or parenteral treatment analyses at the femoral neck (I<sup>2</sup> = 34% and 0%, respectively). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001347-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001347-sec-0111">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001347-sec-0164">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001347-sec-0111"></div> <section id="CD001347-sec-0112"> <h3 class="title" id="CD001347-sec-0112">Summary of main results</h3> <p>We carried out this review to evaluate the benefits and harms of bisphosphonates in GIOP. We examine benefits in terms of fracture outcomes and BMD change; and include subgroup analyses of primary prevention versus treatment. The review provides new data on oral and parenteral bisphosphonates and a direct comparison of low and standard bisphosphonate doses. Harm data include serious adverse events and withdrawals due to adverse events. </p> <section id="CD001347-sec-0113"> <h4 class="title">Fracture Data</h4> <p>The most clinically relevant outcome is the effect of bisphosphonates on fracture prevention. Results from our analyses show that bisphosphonates reduce the total number of incident vertebral fractures by approximately 40% with a NNTB of 31. There was no statistically significant reduction in fractures at nonvertebral sites, including the hip. </p> </section> <section id="CD001347-sec-0114"> <h4 class="title">Harm Data</h4> <p>There were no statistically significant differences in either the incidence of serious adverse events or withdrawals due to adverse events between active drug and control groups. The most frequently reported adverse events in our review were musculoskeletal (myalgias and arthralgias) and upper gastrointestinal; though typically mild in nature and seen in both the bisphosphonate and control groups. Gastrointestinal side effects, or even fear of experiencing them, are cited as a primary reason for decreased compliance or discontinuation of treatment (<a href="./references#CD001347-bbs2-0084" title="PazianasM , AbrahamsenB . Safety of Bisphosphonates. Bone2011;49:103–10. ">Pazianas 2011</a>). Other common associated side effects cited in the literature include transient asymptomatic hypercalcaemia and a transient acute phase response (two to three days of flu‐like symptoms most often associated with the initiation of intravenous treatment). These were seen sporadically in the trials included in our review. </p> <p>Although high‐certainty epidemiological evidence is limited, osteonecrosis of the jaw is a rare but serious adverse event that is associated with bisphosphonate use; specifically with long‐standing use and frequent intravenous dosing (<a href="./references#CD001347-bbs2-0084" title="PazianasM , AbrahamsenB . Safety of Bisphosphonates. Bone2011;49:103–10. ">Pazianas 2011</a>). </p> <p>Bisphosphonates are associated with an increased risk of atypical femur fractures (subtrochanteric or diaphyseal). Estimated incidences vary from 12.5 to 31 of 10,000 people/year with approximately 10 years of alendronate exposure (<a href="./references#CD001347-bbs2-0054" title="AbrahamsenB , EikenP , EastellR . Cumulative alendronate dose and the long‐term absolute risk of subtrochanteric and diaphyseal femur fractures: a register‐based national cohort analysis. Journal of Clinical Endocrinology &amp; Metabolism2010;95(12):5258–65. ">Abrahamsen 2010</a>; <a href="./references#CD001347-bbs2-0063" title="DellR , GreeneD , OttSM , SilvermanS , EisemonE , FunahashiT , et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. Journal of Bone and Mineral Research2012;27(12):2544–50. ">Dell 2012</a>). Current data are conflicting, however most studies agree that the absolute risk of atypical femur fracture with bisphosphonates is low. A recent meta‐analysis pooled nine observational trials and one RCT (n = 658,497) and found a statistically significant increased risk of atypical femur fractures with bisphosphonates; adjusted OR 1.99 (95% CI 1.28 to 3.10) (<a href="./references#CD001347-bbs2-0077" title="LeeS , YinRV , HirparaH , LeeNC , LeeA , LlanosS , et al. Increased risk for atypical fractures associated with bisphosphonate use. Family Practice2015;32(3):276–81. ">Lee 2015</a>). Although the clinical implication is uncertain, both long‐term steroid use and systemic inflammatory disease processes are considered to be risk factors associated with atypical femur fractures (<a href="./references#CD001347-bbs2-0077" title="LeeS , YinRV , HirparaH , LeeNC , LeeA , LlanosS , et al. Increased risk for atypical fractures associated with bisphosphonate use. Family Practice2015;32(3):276–81. ">Lee 2015</a>). </p> <p>Neither osteonecrosis of the jaw nor atypical femur fractures were reported in any of the trials included in our review. </p> <p>Experts still recommend caution in using bisphosphonates in women of childbearing age until further systematic research has been performed (<a href="./references#CD001347-bbs2-0064" title="DjokanovicN , Klieger‐GrossmannC , KorenG . Does treatment with bisphosphonates endanger the human pregnancy?. Journal of Obstetrics and Gynaecology Canada2008;30(12):1146‐8. ">Djokanovic 2008</a>; <a href="./references#CD001347-bbs2-0079" title="LosadaI , SartoriL , DiGianantonioE , ZenM , ClementiM , DoriaA . Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age?. Autoimmunity Reviews2010;9(8):547‐52. ">Losada 2010</a>). </p> </section> <section id="CD001347-sec-0115"> <h4 class="title">BMD Data</h4> <p>Our major BMD outcomes show statistically significant and clinically meaningful increases in bone density at the lumbar spine and femoral neck after 12 months, with MD of 3.50% and 2.06%, respectively. The NNTB at the lumbar spine after 12 months is 3, and the NNTB at the femoral neck after 12 months is 5. It is generally believed that steroid‐induced bone loss is not as prominent in cortical bone (<a href="./references#CD001347-bbs2-0087" title="RickersH , DedingA , ChristiansenC , RodbroP . Mineral loss in cortical and trabecular bone during high‐dose prednisone treatment. Calcified Tissue International1984;36(3):269–73. ">Rickers 1984</a>) and that changes in BMD are not as dramatic at the femoral neck, as it takes longer for cortical bone to turn over. Our results support these beliefs and data from the placebo arms of the trials show a smaller magnitude of bone loss at the femoral neck than the lumbar spine. </p> <p>Our NNTBs for the change in BMD at the lumbar spine and femoral neck are based on an SMD of 0.5 as an estimate of the minimal clinically important difference for BMD change (<a href="./references#CD001347-bbs2-0092" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.handbook.cochrane.org. ">Schünemann 2011b</a>). It is difficult to express our findings in terms of a minimally clinically relevant change in BMD as that value has not been established for GIOP. Fractures in GIOP often occur at a higher BMD than seen in primary osteoporosis and, unlike primary osteoporosis, a predictable correlation between BMD and fracture risk has not been established in the GIOP setting. Furthermore, improvement in BMD only accounts for a small part of the reduction in vertebral fracture risk observed with antiresorptive therapy (<a href="./references#CD001347-bbs2-0060" title="Cummings , S.R , Karpf , D.B , Harris , F , Genant , H.K , Ensrud , K , LaCroix , A.Z , et al. Improvement in Spine Bone Density and Reduction in Risk of Vertebral Fractures during Treatment with Antiresorptive Drugs. American Journal of Medicine2002;112:281‐9. ">Cummings 2002</a>; <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a>; <a href="./references#CD001347-bbs2-0089" title="SaagKG . Glucocorticoid‐induced osteoporosis. Endocrinology and Metabolism Clinics of North America2003;32:135‐57. ">Saag 2003</a>; <a href="./references#CD001347-bbs2-0096" title="VanStaaTP , LeufkensHGM , CooperC . The Epidemiology of Corticosteroid‐Induced Osteoporosis: a Meta‐analysis. Osteoporosis International2002;13:777‐87. ">Van Staa 2002</a>). </p> <p>A previous meta‐analysis evaluating BMD improvements and vertebral fracture risk reduction in postmenopausal women and elderly men suggests that each 1% improvement in spine BMD during anti‐resorptive therapy is associated with a 0.03 decrease in relative risk of vertebral fracture (<a href="./references#CD001347-bbs2-0060" title="Cummings , S.R , Karpf , D.B , Harris , F , Genant , H.K , Ensrud , K , LaCroix , A.Z , et al. Improvement in Spine Bone Density and Reduction in Risk of Vertebral Fractures during Treatment with Antiresorptive Drugs. American Journal of Medicine2002;112:281‐9. ">Cummings 2002</a>). Although the meta‐analysis is neither specific to GIOP nor to bisphosphonates; it does provide a rough clinical context to consider our findings of a 3.5% difference between treatment and control group lumbar spine BMD after 12 months of bisphosphonate therapy. </p> <p>The natural history of patients starting steroid therapy based on control arms in our prevention trials is to see a 1% to 6% decrease in lumbar spine BMD and 1% to 4% decrease in femoral neck BMD in the first year of treatment. </p> <p>We were interested in analysing the prevention and treatment trials separately as the two clinical scenarios are distinct. In general, the prevention trials showed greater bone loss in the control arm with maintenance or small bone accrual in the treatment arm. In contrast, the treatment trials showed a greater degree of accrual in the treatment arm with less dramatic bone loss in the control arm. This supports the belief that bone loss is more prominent in the early stages of corticosteroid therapy, with a slower rate of loss as therapy continues. As such, prophylactic therapy demonstrates an ability to reduce bone loss, whereas bisphosphonate treatment provides an opportunity to build bone mass in chronic steroid‐using people. </p> <p>We included post‐hoc subgroup analyses based on gender and menopausal status (men, premenopausal women, postmenopausal women) however we are cautious in interpreting these results because subgroup comparisons are observational in nature (<a href="./references#CD001347-bbs2-0062" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We found that there remains a similar magnitude of effect in the subgroups as compared to the whole group analyses except for a wider spread of variability, perhaps due to fewer trials in each analysis. Results for the female groups at the femoral neck were not statistically significant. There was no significant heterogeneity in the male analyses but significant heterogeneity in the female plots. <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a> was a visible outlier in the female plots and differed from the other trials by its use of parenteral bisphosphonates, which may explain such a difference. Our a priori sensitivity analyses that separated oral and enteral bisphosphonates revealed that heterogeneity was likely in part due to this factor. Removal of <a href="./references#CD001347-bbs2-0009" title="FredianiB , FalsettiP , BaldiF , AcciaiC , FilippouG , MarcolongoR . Effects of 4‐year treatment with once‐weekly clodronate on prevention of corticosteroid‐induced bone loss and fractures in patients with arthritis: evaluation with dual‐energy X‐ray absorptiometry and quantitative ultrasound. Bone2003;33:575‐81. ">Frediani 2003</a> reduced the I<sup>2</sup> statistic in all female analyses (I<sup>2</sup>= 0% for premenopausal lumbar spine BMD analysis; I<sup>2</sup>= 43% for postmenopausal lumbar spine BMD analysis; I<sup>2</sup>= 0% for premenopausal and postmenopausal femoral neck BMD analyses; results not shown). These post‐hoc analyses included mixed data from prevention and treatment trials. Sub‐subgroup analyses, broken down by gender and prevention or treatment, could not be performed as data were not presented in the trials at that level of detail. </p> <p>Given the poor absorption of oral bisphosphonates (<a href="./references#CD001347-bbs2-0068" title="GertzBJ , HollandSD , KlineWF , MatuszewskiBK , FreemanA , QuanH , et al. Studies on the oral availablility of alendronate. Clinical Pharmacology &amp; Therapeutics1995;58(3):288‐98. ">Gertz 1995</a>; <a href="./references#CD001347-bbs2-0088" title="RussellRG , XiaZ , DunfordJE , OppermannU , KwaasiA , HulleyPA , et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Annals of the New York Academy of Sciences2007;1117:209‐57. ">Russell 2007</a>) there is perceived differential efficacy based on route of administration. Our analysis showed that the effect size of BMD at lumbar spine differed between parenteral bisphosphonate trials and oral bisphosphonate trials (5.12% and 3.25%, respectively). This difference in effect size between the parenteral analysis and oral analysis was also seen at the femoral neck (4.56% and 1.92%, respectively). In the lumbar spine BMD analysis all parenteral bisphosphonates were prevention studies which likely contributed to the significant heterogeneity in the lumbar spine BMD prevention subgroup analysis. A sub‐subgroup analysis of parenteral and oral bisphosphonates subsequently eliminated the heterogeneity in the lumbar spine BMD prevention subgroup. </p> <p>There are few head‐to‐head trials of oral versus parenteral bisphosphonates in GIOP. A 12‐month RCT including 265 men, divided into prevention and treatment subgroups, compared a single 5 mg infusion of zoledronic acid to 5 mg daily oral risedronate. The authors found a statistically significant increase in lumbar spine BMD of 2.7% (95% CI 0.99% to 4.43%) with zoledronic acid over risedronate in their prevention subgroup. The treatment difference at the femoral neck was not statistically significant in the prevention subgroup at 1.38% (95% CI ‐0.18% to 2.95%) (<a href="./references#CD001347-bbs2-0090" title="SambrookPN , RouxC , DevogelaerJP , SaagK , LauCS , ReginsterJY , et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone2012;50:289–95. ">Sambrook 2012</a>). Another RCT (n = 771) found statistically significant improvements in BMD at 12 months with zoledronic acid over risedronate at both the lumbar spine and femoral neck in the prevention subgroups; 1.96% (95% CI 1.04 to 2.88) and 1.33% (95% CI 0.41% to 2.25%) (<a href="./references#CD001347-bbs2-0085" title="ReidDM , DevogelaerJP , SaagK , RouxC , LauCS , ReginsterJY , et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid‐induced osteoporosis (HORIZON): a multicentre, double‐blind, double‐dummy, randomised controlled trial. Lancet2009;373:1253–63. ">Reid 2009</a>). Overall, parenteral regimes were vastly preferred over oral regimes in these trials. Route of administration is a factor to be considered in the treatment of GIOP. </p> <p>We analysed head‐to‐head comparisons of the low‐ and standard‐dose bisphosphonate treatment groups in five studies (<a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>). The standard‐dose bisphosphonate groups showed a small increase in benefit at the lumbar spine (0.95%, 95% CI 0.37% to 1.53%). The data suggest that even low‐dose bisphosphonates can be beneficial in the treatment of GIOP. </p> <p>It was interesting to see that an ad‐hoc pooled analysis of low‐dose bisphosphonates (<a href="./references#CD001347-bbs2-0005" title="BoutsenY , JamartJ , EsselinckxW , DevogelaerJP . Primary prevention of glucocorticoid‐induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1‐year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone &amp; Mineral Research2001;16:104‐12. ">Boutsen 2001</a>; <a href="./references#CD001347-bbs2-0006" title="CohenS , LevyRM , KellerM , BolingE , EmkeyRD , GreenwaldM , et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis &amp; Rheumatism1999;42:2309‐18. ">Cohen 1999</a>; <a href="./references#CD001347-bbs2-0014" title="LemsWF , LodderMC , LipsP , BijlsmaJW , GeusensP , SchrameijerN , et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‐dose prednisone: a randomized, double‐blind, placebo‐controlled trial. Osteoporosis International2006;17:716‐23. ">Lems 2006</a>; <a href="./references#CD001347-bbs2-0017" title="ReidDM , HughesRA , LaanRF , Sacco‐GibsonNA , WenderothDH , AdamiS , et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. European Corticosteroid‐Induced Osteoporosis Treatment Study. Journal of Bone &amp; Mineral Research2000;15:1006‐13. ">Reid 2000</a>; <a href="./references#CD001347-bbs2-0020" title="SaagKG , EmkeyR , SchnitzerTJ , BrownJP , HawkinsF , GoemaereS , et al. Alendronate for the prevention and treatment of glucocorticoid‐induced osteoporosis. New England Journal of Medicine1998;339:292‐9. ">Saag 1998</a>) compared to treatment with calcium or vitamin D alone resulted in a mean difference of 3.15% (95% CI 1.87% to 4.44%) at the lumbar spine. This effect size is not out of the range of our pooled estimate for all studies using standard‐dose bisphosphonates supporting the suggestion that low‐dose bisphosphonates may be beneficial (results not shown). </p> <p>There is a perception that newer bisphosphonates are more effective than etidronate in treating osteoporosis. In both the vertebral fracture analyses and both the BMD analyses of oral bisphosphonates there was no heterogeneity among the studies, which included three different types of bisphosphonates. We did not perform a post‐hoc analysis on newer bisphosphonates. </p> <p>One critique of bisphosphonate studies is the lack of long‐term follow‐up. For this updated review we decided to include the analysis of BMD at the lumbar spine and femoral neck after 18 to 24 months. Results from these analyses show increases in bone density at the lumbar spine and femoral neck with mean differences of 5.49% and 3.28%, respectively. This suggests ongoing efficacy up to two years. </p> </section> </section> <section id="CD001347-sec-0116"> <h3 class="title" id="CD001347-sec-0116">Overall completeness and applicability of evidence</h3> <p>This updated review examined the evidence from 27 RCTs for the use of bisphosphonates in the prevention and treatment of GIOP. We included 25 new studies for this update, and, due to more rigorous inclusion criteria, only two of the 13 studies from the existing review, as there were numerous higher quality studies published since the original review. A variety of outcomes measured both the benefits and the harms of bisphosphonates. Benefits included decreased bone loss or bone accrual at both the lumbar spine and femoral neck and a reduced risk of vertebral fractures. Although fracture outcome data may have more direct clinical relevance than BMD outcome measurements, most GIOP studies reported BMD as the primary outcome. Vertebral fracture data were sufficient to address the objectives of our review, however data on nonvertebral fractures often lacked detail and we were unable to examine the incidence of hip and wrist fractures separately. None of the trials reported on quality of life so we were unable to include this as an outcome measure in our review. </p> <p>This updated review provides confirmatory evidence that bisphosphonates, alone or in combination with calcium or vitamin D, or both, are more beneficial than calcium or vitamin D, or both, alone or with placebo, for both the prevention and treatment of GIOP at the hip and spine. The trials used in this review used similar inclusion criteria, however the participant groups differed between trials in terms of the prior steroid usage, baseline BMD measurements and prevalent fractures. This updated review provides new data on the benefits of bisphosphonates in reducing the risk of vertebral fractures and the prevention versus treatment of GIOP. We provide new data on the different effect sizes seen in oral and parenteral bisphosphonate clinical trials, and the potential benefit of low‐dose bisphosphonates. </p> <p>Regarding bisphosphonate harms, we could not find any statistically significant differences in the occurrence of serious adverse events or withdrawals due to adverse events between the bisphosphonate and control groups. In nine of the trials analysed, the protocols for the collection of harm data were unclear and may have resulted in biased results. Some of the included studies based their power calculations solely on benefit outcomes and may not have been sufficiently powered to adequately assess harm outcomes. Although findings on serious adverse events and withdrawals due to adverse events are important to consider in evaluating bisphosphonate therapy, we are cautious in interpreting these data as markers for harm and tolerability due to the potential for bias (<a href="./references#CD001347-bbs2-0073" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> </section> <section id="CD001347-sec-0117"> <h3 class="title" id="CD001347-sec-0117">Quality of the evidence</h3> <p>The <a href="./full#CD001347-tbl-0001">summary of findings Table for the main comparison</a> shows the overall certainty and importance of the body of evidence using the GRADE Working Group Approach (<a href="./references#CD001347-bbs2-0093" title="SchünemannH , BrożekJ , GuyattG , OxmanA , (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. ">Schünemann 2013</a>). We rated the certainty of the evidence for vertebral fractures as high, which indicates that further research is very unlikely to change our confidence in the estimate of effect. We downgraded the nonvertebral fracture outcome to low‐certainty evidence for imprecision due to a total sample size below the calculated optimal information size, and risk of bias for being a patient‐reported subjective outcome. We rated the certainty of remaining outcomes as moderate, which indicates that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. BMD outcomes were downgraded for indirectness as surrogate markers for osteoporosis. Serious adverse events and withdrawals due to adverse events were downgraded for imprecision due to small total sample size and 95% CI including the possibility of no effect and appreciable harm. We assessed all outcomes as important in terms of their impact on decisions regarding optimal management. </p> </section> <section id="CD001347-sec-0118"> <h3 class="title" id="CD001347-sec-0118">Potential biases in the review process</h3> <p>Our methods and reporting are based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> recommendations (<a href="./references#CD001347-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We devised a thorough search strategy with no language restrictions and believe that we identified all relevant studies. Two review authors in various combinations independently assessed the trials for inclusion in the review, assessed risk of bias and extracted data for analysis. The biggest limitations of the review process were the heterogeneity between the trials, likely related to different patient characteristics (differences in underlying inflammatory conditions, steroid doses, and prevalent fractures) and that some trials reported outcomes but did not provide data in a form that could be extracted for meta‐analysis. </p> </section> <section id="CD001347-sec-0119"> <h3 class="title" id="CD001347-sec-0119">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are similar to those reported in the 1999 Cochrane Review evaluating the efficacy of bisphosphonates in steroid‐induced osteoporosis (<a href="./references#CD001347-bbs2-0098" title="HomikJ , CranneyA , SheaB , TugwellP , WellsGA , AdachiJ , et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews1999, Issue 1 Art. No.: CD001347. [DOI: 10.1002/14651858.CD001347] ">Homik 1999</a>). As there were very few high‐quality papers included in the original review, this updated review includes data from only two of the 13 studies that were included in the original version. Therefore, the effect estimates have changed. While the original review was not able to establish bisphosphonate benefit beyond one year or against spinal fractures, the meta‐analyses in this updated review have provided conclusive data on the above measures of benefit. </p> <p>A subsequent systematic review by the Health Technology Assessment programme of the NHS by <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> assessed the clinical effectiveness of numerous active and inactive treatments for GIOP. Outcome measures included incident vertebral fractures, incident nonvertebral fractures, associated effects, compliance and continuance. <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> included 23 bisphosphonate studies, of which only eight overlap with the 27 studies in our updated review. Many of the studies in <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> were not eligible for inclusion in our review for using active comparators or including participants with transplant‐associated steroid use. <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> analysed different bisphosphonate types individually and found that, in the non‐transplant population, only risedronate 5 mg/day showed a statistically significant reduction in vertebral fractures as compared to placebo or no treatment. No intervention was shown to be beneficial in preventing nonvertebral fractures. In our analysis of vertebral fractures nine of the 10 studies used alendronate and showed a statistically significant reduction in vertebral fractures. </p> <p>There are some other differences between our updated review and that of <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a>. Our review includes 14 bisphosphonate trials that were not included in <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> because fracture was not the primary outcome. Our fracture analyses include only studies with standardised radiographic screening of vertebral fractures in order to ensure complete capture of fracture incidence, whereas many of the studies in <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a> report only symptomatic fractures. It is known that up to 65% of vertebral fractures may be asymptomatic (<a href="./references#CD001347-bbs2-0059" title="CooperC , AtkinsonEJ , O'FallonWM , MeltonJK3rd . Incidence of clinically diagnosed vertebral fractures: a population‐based study in Rochester, Minnesota, 1985‐1989. Journal of Bone and Mineral Research1992;7:221‐7. ">Cooper 1992</a>; <a href="./references#CD001347-bbs2-0074" title="KanisJA , StevensonM , McCloskeyEV , DavisS , Lloyd‐JonesM . Glucocorticoid‐induced osteoporosis: a systematic review and cost–utility analysis. Health Technology Assessment2007;11:7. ">Kanis 2007</a><i>).</i> Combining all types of bisphosphonate in our pooled analyses allows for a stronger effect size estimate. As their report shows, most studies only achieved statistically significant findings in pooled analyses. </p> <p>Current American College of Rheumatology clinical practice guidelines for post‐menopausal women and men 50 years old or more recommend bisphosphonate therapy for GIOP based on FRAX risk assessment (<a href="./references#CD001347-bbs2-0070" title="GrossmanJM , GordonR , RanganathVK , DealC , CaplanL , ChenW . American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Care and Research2010;62(11):1515‐26. ">Grossman 2010</a>). Bisphosphonate therapy is recommended in low‐risk patients (FRAX &lt; 10% for 10‐year major osteoporotic fracture) on corticosteroid treatment for greater or equal to 7.5 mg/day for three or more months' duration; moderate‐risk patients (FRAX 10% to 20%) on doses less than 7.5 mg/day for three or more months' duration; and high‐risk patients (FRAX &gt; 20%) on any dose and duration of corticosteroid (<a href="./references#CD001347-bbs2-0070" title="GrossmanJM , GordonR , RanganathVK , DealC , CaplanL , ChenW . American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Care and Research2010;62(11):1515‐26. ">Grossman 2010</a>). In comparison, the International Osteoporosis Foundation and European Calcified Tissue Society framework for GIOP management of post‐menopausal women and men 50 years old or more recommend treatment to be considered in patients on corticosteroid treatment greater or equal to 7.5 mg/day for three or more months' duration with a previous fracture or that are greater than 70 years of age (<a href="./references#CD001347-bbs2-0078" title="LekamwasamS , AdachiJD , AgnusdeiD , BilezikianJ , BoonenS , BorgströmF , et al. A framework for the development of guidelines for the management of glucocorticoid‐induced osteoporosis. Osteoporosis International2012;23(9):2257‐76. ">Lekamwasam 2012</a>). For those with no previous fracture, younger than 70 years, or on corticosteroid doses less than 7.5 mg/day, FRAX assessment with or without BMD assessment is recommended to further guide decision‐making (<a href="./references#CD001347-bbs2-0078" title="LekamwasamS , AdachiJD , AgnusdeiD , BilezikianJ , BoonenS , BorgströmF , et al. A framework for the development of guidelines for the management of glucocorticoid‐induced osteoporosis. Osteoporosis International2012;23(9):2257‐76. ">Lekamwasam 2012</a>). Our study supports the use of bisphosphonates in people who are either starting corticosteroids or on established corticosteroid therapy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001347-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001347-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001347-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001347-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bisphosphonates vs control: benefits ‐ fractures, Outcome 1 Incident radiographic vertebral fractures 12‐24 months." data-id="CD001347-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Bisphosphonates vs control: benefits ‐ fractures, Outcome 1 Incident radiographic vertebral fractures 12‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bisphosphonates vs control: benefits ‐ fractures, Outcome 2 Incident radiographic nonvertebral fractures 12‐24 months." data-id="CD001347-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Bisphosphonates vs control: benefits ‐ fractures, Outcome 2 Incident radiographic nonvertebral fractures 12‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 1 LS BMD change 12 months: all trials." data-id="CD001347-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 1 LS BMD change 12 months: all trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 2 LS BMD change 12 months: oral treatment." data-id="CD001347-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 2 LS BMD change 12 months: oral treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 3 LS BMD change 12 months: parenteral treatment." data-id="CD001347-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 3 LS BMD change 12 months: parenteral treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 4 LS BMD change 12 months: low‐ vs standard‐dose." data-id="CD001347-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 4 LS BMD change 12 months: low‐ vs standard‐dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 5 LS BMD change 18‐24 months." data-id="CD001347-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 5 LS BMD change 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 6 LS BMD change 12 months prevention trials: oral and parenteral subgroups." data-id="CD001347-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 6 LS BMD change 12 months prevention trials: oral and parenteral subgroups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 7 LS BMD change 12 months: gender/menopausal status subgroups." data-id="CD001347-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS), Outcome 7 LS BMD change 12 months: gender/menopausal status subgroups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 1 FN BMD change 12 months: all trials." data-id="CD001347-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 1 FN BMD change 12 months: all trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 2 FN BMD change 12 months: oral treatment." data-id="CD001347-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 2 FN BMD change 12 months: oral treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 3 FN BMD change 12 months: parenteral treatment." data-id="CD001347-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 3 FN BMD change 12 months: parenteral treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 4 FN BMD change 12 months: low‐ vs standard‐dose." data-id="CD001347-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 4 FN BMD change 12 months: low‐ vs standard‐dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 5 FN BMD change 18‐24 months." data-id="CD001347-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 5 FN BMD change 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 6 FN BMD change 12 months: gender/menopausal status subgroups." data-id="CD001347-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN), Outcome 6 FN BMD change 12 months: gender/menopausal status subgroups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bisphosphonates vs control: harms, Outcome 1 Serious adverse events 12‐24 months." data-id="CD001347-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Bisphosphonates vs control: harms, Outcome 1 Serious adverse events 12‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001347-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/urn:x-wiley:14651858:media:CD001347:CD001347-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_t/tCD001347-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bisphosphonates vs control: harms, Outcome 2 Withdrawals due to adverse events 12‐24 months." data-id="CD001347-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Bisphosphonates vs control: harms, Outcome 2 Withdrawals due to adverse events 12‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/media/CDSR/CD001347/image_n/nCD001347-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001347-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates versus control for adults with GIOP</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonates (alone or with calcium and/or vitamin D) compared with control (calcium and/or vitamin D and/or placebo) for adults with GIOP</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with GIOP </p> <p><b>Settings:</b> ambulatory </p> <p><b>Intervention:</b> bisphosphonates (alone or with calcium and/or vitamin D) </p> <p><b>Comparison:</b> control (calcium and/or vitamin D and/or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (calcium and/or vitamin D and/or placebo)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bisphosphonates (alone or with calcium and/or vitamin D) </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incident vertebral fractures</b> </p> <p>Radiographic follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (27 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.35 to 0.91) </p> <p><b>RD ‐0.02</b> (‐0.05 to </p> <p>0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1343<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute increased benefit 2% fewer people with fractures using bisphosphonates (95% CI 5.00% fewer to 1.00% more) </p> <p>Relative per cent change 43% improvement with bisphosphonates (95% CI 9.00% to 65.00% better) </p> <p>NNTB = 31 (95% CI 20 to 145)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incident nonvertebral fractures</b> </p> <p>Radiographic follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> <br/> (25 to 69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.79</b> (0.47 to 1.33) </p> <p><b>RD ‐0.01</b> (‐0.04 to 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1245<br/> (9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased benefit 1% fewer people with fractures using bisphosphonates (95% CI 4.00% fewer to 1.00% more) </p> <p>Relative per cent change 21% improvement with bisphosphonates (95% CI 33.00% worse to 53.00% better) </p> <p>NNTB = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lumbar spine BMD</b> </p> <p>DEXA follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean per cent change in BMD across control groups was <b>‐3.19%</b> (‐8.08% to 1.70%) from baseline<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean per cent change in BMD from baseline in bisphosphonate groups was <b>3.50% higher</b> than control groups (2.90% to 4.10% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2042<br/> (23 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,7,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute increased benefit 3.50% with bisphosphonates (95% CI 2.90 to 4.10)</p> <p>Relative per cent change 1.10% (95% CI 0.91 to 1.29) with bisphosphonates</p> <p>NNTB = 3 (95% CI 2 to 3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Femoral neck BMD</b> </p> <p>DEXA follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean per cent change in BMD across control groups was <b>‐1.59%</b> (‐10.49% to 7.31%) from baseline <sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean per cent change in BMD from baseline in bisphosphonate groups was <b>2.06% higher</b> than control groups (1.45% to 2.68% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1665<br/> (18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7,8</sup> </p> <p>due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased benefit 2.06% with bisphosphonates (95% CI 1.45 to 2.68)</p> <p>Relative per cent change 1.29% with bisphosphonates (95% CI 0.91 to 1.69)</p> <p>NNTB = 5 (95% CI 4 to 7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p>follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>147 per 1000</b> <br/> (120 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b> (0.74 to 1.12) </p> <p><b>RD 0.00</b> (‐0.02, 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1703<br/> (15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>low</b><sup>3,9</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased harm 0% more adverse events with bisphosphonates (95% CI 2.00% fewer to 2.00% more) </p> <p>Relative per cent change 9% improvement with bisphosphonates (95% CI 12.00% worse to 26.00% better) </p> <p>NNTH = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> <p>follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>77 per 1000</b> <br/> (56 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.06</b> (0.77 to 1.47) </p> <p><b>RD 0.01</b> (‐0.01 to 0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1790<br/> (15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>low</b><sup>3,9</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute increased harm 1% more withdrawals with bisphosphonates (95% CI 1.00% fewer to 3.00% more) </p> <p>Relative per cent change 6% worsening with bisphosphonates (95% CI 47.00% worse to 23.00% better) </p> <p>NNTH = n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not assessed by any of the trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>RD:</b> Risk Difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Vertebral fractures meet calculated OIS threshold of 1174 (calculation not shown ‐ <a href="./references#CD001347-bbs2-0056" title="Brant , R . Inference for Proportions: Comparing Two Independent Samples. Accessed June 12 2015: stat.ubc.ca/˜rollin/stats/ssize/b2.html, 2014. ">Brant 2014</a>) </p> <p><sup>2</sup>Downgraded for risk of bias: nonvertebral fractures were a patient‐reported, subjective outcome </p> <p><sup>3</sup>Downgraded for imprecision: total sample size is below calculated optimal information size (OIS) (calculations not shown ‐ <a href="./references#CD001347-bbs2-0056" title="Brant , R . Inference for Proportions: Comparing Two Independent Samples. Accessed June 12 2015: stat.ubc.ca/˜rollin/stats/ssize/b2.html, 2014. ">Brant 2014</a>) and the 95% confidence interval around the pooled estimate of effect includes both the possibility of no effect and appreciable benefit or harm </p> <p><sup>4</sup>Number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) is not applicable when result is not statistically significant </p> <p><sup>5</sup>We calculated mean baseline risk for the control group in RevMan using generic inverse variance (calculations not shown) </p> <p><sup>6</sup>Most heterogeneity explained through sensitivity analyses </p> <p><sup>7</sup>Downgraded for indirectness: bone density is a surrogate marker for fracture risk </p> <p><sup>8</sup>Clinically relevant change in BMD: the natural history of participants starting steroid therapy based on control arms in our prevention trials is to see a 1%‐6% decrease in lumbar spine BMD and 1%‐4% decrease in femoral neck BMD in the first year of treatment. We have used an SMD of 0.5 as an estimate of the minimal clinically important difference for BMD change to calculate the NNTB (<a href="./references#CD001347-bbs2-0092" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.handbook.cochrane.org. ">Schünemann 2011b</a>) </p> <p><sup>9</sup>Downgraded for risk of bias: the protocols for the collection of harm data in a large number of trials were unclear </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates versus control for adults with GIOP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/full#CD001347-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001347-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ fractures</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incident radiographic vertebral fractures 12‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.35, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incident radiographic nonvertebral fractures 12‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ fractures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001347-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 LS BMD change 12 months: all trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [2.90, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prevention trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [2.90, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Treatment trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [2.64, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LS BMD change 12 months: oral treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [2.88, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LS BMD change 12 months: parenteral treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [2.35, 7.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 LS BMD change 12 months: low‐ vs standard‐dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.37, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 LS BMD change 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.49 [3.47, 7.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 LS BMD change 12 months prevention trials: oral and parenteral subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [2.90, 4.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oral bisphosphonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [2.75, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Parenteral bisphosphonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [2.35, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 LS BMD change 12 months: gender/menopausal status subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [2.03, 5.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [2.68, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Premenopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [1.50, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Postmenopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [0.65, 8.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at lumbar spine (LS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001347-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 FN BMD change 12 months: all trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.45, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prevention trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [1.99, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Treatment trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.73, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 FN BMD change 12 months: oral treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.31, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FN BMD change 12 months: parenteral treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [2.07, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FN BMD change 12 months: low‐ vs standard‐dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [‐0.42, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 FN BMD change 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [1.70, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FN BMD change 12 months: gender/menopausal status subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [1.65, 4.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [1.15, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Premenopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐0.96, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Postmenopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.62 [‐0.37, 7.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Bisphosphonates vs control: benefits ‐ bone mineral density (BMD) at femoral neck (FN)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001347-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bisphosphonates vs control: harms</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events 12‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to adverse events 12‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.77, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bisphosphonates vs control: harms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001347.pub2/references#CD001347-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001347.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001347-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001347-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001347-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001347-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001347-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD001347-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD001347-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001347-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001347\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001347\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001347\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001347\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001347\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001347.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001347.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001347.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001347.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001347.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726180587"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001347.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726180591"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001347.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8d5ebeeaf431',t:'MTc0MDcyNjE4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 